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Normal Glycolytic Enzyme Activity is Critical for Hypoxia Inducible Factor-1α Activity and 
Provides Novel Targets for Inhibiting Tumor Growth 
 
By Geoffrey Grandjean 
Advisory Professor: Garth Powis, D. Phil 
 
Unique to proliferating cancer cells is the observation that their increased need for energy is 
provided by a high rate of glycolysis followed by lactic acid fermentation in a process known as 
the Warburg Effect, a process many times less efficient than oxidative phosphorylation 
employed by normal cells to satisfy a similar energy demand [1].  This high rate of glycolysis 
occurs regardless of the concentration of oxygen in the cell and is typically at rates significantly 
higher than those found in normal cells of the same tissue type. Unlike the case of proliferating 
cancer cells in culture, the internal environment of most solid tumors is hypoxic due to an 
inadequate or disorganized blood supply leading to even greater increases in glycolytic rates 
and, therefore, lactic acid production [2].  The regulation of glycolytic enzyme expression by the 
hypoxia-inducible factor 1 alpha (HIF-1α) transcription factor in states of low oxygen stress is a 
well described phenomenon [3, 4].  Through the use of a high throughput siRNA screen using an 
siRNA library targeting all the known open reading frames of the human genome (Dharmacon, 
Inc.), novel regulators of HIF-1α were identified including many enzymes involved in the 
glycolytic pathway. Here, I describe a novel relationship between glycolysis and its regulation of 
HIF-1α activity. Our studies have shown that of the 40 enzymes of glycolysis involving 11 
enzymatic steps and various enzyme isoforms, siRNA knockdown of Aldolase A (ALDOA) 
produces the maximum inhibition of HIF-1α activity in vitro – a finding that I have subsequently 
confirmed in a murine in vivo model. Further study indicated that this is mediated through a 
mechanism involving AMPK, a sensor of low ATP levels, and the subsequent dissociation of 
HIF-1α and p300, a critical co-activator of HIF-1α. ALDOA was chosen as the molecular target 
 vi 
for a drug discovery effort because it produced maximum inhibition of cancer growth and would 
serve as a dual glycolysis and HIF-1α inhibitor, thus blocking two important cancer cell survival 
mechanisms at the same time. 
Tumor hypoxia is a pervasive problem in regards to treatment options as hypoxic tumor cells 
are resistant to traditional chemo and radiotherapies.  Thus, the overreaching goal of this 
research is to identify viable dual inhibitors of energy production and specific stress survival 
pathways to be used as a combinatorial therapy for patients in which tumor hypoxia has 
rendered standard therapeutic tools ineffective. 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
Table of Contents: 
Approval Page ............................................................................................................................... i 
Title Page ....................................................................................................................................... ii 
Acknowledgements ....................................................................................................................... iii 
Abstract ......................................................................................................................................... iv 
Table of Contents ......................................................................................................................... vi 
List of Illustrations ......................................................................................................................... ix 
List of Tables ............................................................................................................................... xii 
List of Abbreviations ................................................................................................................... xiii 
Introduction ................................................................................................................................... 1 
Glycolysis and Cancer ...................................................................................................... 1 
Anaerobic Glycolysis ......................................................................................................... 4 
Tumor Hypoxia as an Inducer of Glycolysis ...................................................................... 4 
Inhibitors of Glycolysis as Cancer Drugs .......................................................................... 5 
HIF-1 as a Tumor Survival Factor and Cancer Drug Target ............................................. 5 
Aldolase A as a Cancer Drug Target ................................................................................ 6 
Summary ........................................................................................................................... 7 
Materials and Methods ................................................................................................................. 8 
Cells and Culture Conditions ............................................................................................ 8 
Creation of Stable and Inducible Cell Lines ...................................................................... 8 
siRNA Screening ............................................................................................................... 9 
Individual siRNA Transfection ......................................................................................... 13 
 viii 
Determination of Cellular ATP Concentration ................................................................. 14 
Xenograft Analysis .......................................................................................................... 14 
Molecular Modeling ......................................................................................................... 15 
Target Receptor and Chemical Database Selection ........................................... 15 
Virtual Screening ................................................................................................. 15 
Aldolase Enzymatic Assay .............................................................................................. 16 
Measurement of Cellular Glycolysis ................................................................................ 21 
Crystallization and Structure Solution ............................................................................. 22 
The Cancer Genome Atlas Data Analysis ...................................................................... 22 
Chapter 1: Identification of a Novel Feed Forward Loop ............................................................ 24 
Glycolytic Enzymes Regulate HIF-1α Activity ................................................................. 25 
HIF-1α Activity is Mediated by AMPK Activation and EP300 Inactivation ....................... 40 
Variable Expression of Aldolase Isoforms Suggest Compensatory Effects on Glycolysis
 ........................................................................................................................................ 50 
Inducible ALDOA Knockdown Extends Median Survival in an in vivo Model of Metastatic 
Breast Cancer ................................................................................................................. 55 
Discussion ....................................................................................................................... 62 
Chapter 2: Designing a Chemical Probe .................................................................................... 65 
Virtual High Throughput Screening Quickly Characterizes Potential Lead Compounds 66 
High Throughput Small Molecule Screen in vitro Uncovers Novel Pharmacological 
Probes ............................................................................................................................. 75 
Discussion ....................................................................................................................... 79 
 ix 
Chapter 3: Developing a Novel ALDOA Inhibitor ........................................................................ 81 
Identification of Lead Compound Based on Time Dependent Inhibition of ALDOA in 
Biochemical Assay .......................................................................................................... 82 
X-Ray Crystallography Implies Cysteine Residues Distal to Active Site are Critical for 
Normal Aldolase Function ............................................................................................... 84 
Assessment of Glycolytic Substrates, Intermediates, and Products Suggests ALDO 
Inhibition .......................................................................................................................... 86 
TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo ................................................... 90 
Discussion ....................................................................................................................... 92 
Chapter 4: Summary and Future Directions ............................................................................... 94 
Future Directions: Glycolytic Regulation of HIF Activity .................................................. 95 
Future Directions: TDZD-8 and Analogs’ Mechanism of Action ...................................... 97 
Summary ......................................................................................................................... 98 
References ................................................................................................................................. 99 
 
 
 
 
 
 
 
 
 
 
 x 
List of Illustrations : 
Introduction : 
Figure 1 : Glycolysis/HIF-1 Feed Forward Cycle in Cancer ......................................................... 3 
Figure 2 : siRNA Transfection Optimization Format .................................................................. 10 
Figure 3 : Optimization of Hypoxia Conditions for High Throughput Screening ........................ 12 
Figure 4: Optimization of High Throughput Drug Screening Assay ........................................... 18 
Figure 5: High Throughput Small Molecule Screening Protocol Schematic .............................. 20 
Chapter 1: 
Figure 6: Viability / HIF Activity Following siRNA Knockdown of Glycolytic Enzymes (MIA PaCa-
2) ................................................................................................................................................. 27 
Figure 7: Viability / HIF Activity Following siRNA Knockdown of Glycolytic Enzymes (PANC-1)
 .................................................................................................................................................... 28 
Figure 8: Viability / HIF Activity Following siRNA Knockdown of Glycolytic Enzymes (MDA-MB-
231) ............................................................................................................................................. 29 
Figure 9: Viability / HIF Activity Following siRNA Knockdown of Glycolytic Enzymes (HT-29) . 30 
Figure 10: Glycolytic Enzyme Expression Required for Global HIF Activity .............................. 32 
Figure 11: Dual Transfections Show Redundant Activity of PGK Isoforms ............................... 36 
Figure 12: ALDO and PGK Isoform Knockdown Inhibits Cellular Glycolysis  ............................ 37 
Figure 13: ALDO and PGK Isoform Knockdown Inhibits Cellular ATP Production .................... 38 
Figure 14: ALDO and PGK Isoform Knockdown Inhibits HIF Activity Without Loss of HIF Protein 
 .................................................................................................................................................... 40 
Figure 15: Dual Transfections Indicate AMPK Regulation of HIF Activity Following Glycolytic 
Enzyme Knockdown ................................................................................................................... 41 
 xi 
Figure 16: AMPK Knockdown Using siRNA or Compound C Rescues HIF Activity .................. 42 
Figure 17: Western Blot Showing that ALDOA Knockdown Leads to Hyper Activation of AMPK 
 .................................................................................................................................................... 43 
Figure 18: Western Blot Showing that ALDOA Knockdown Leads to Hyper Activation of AMPK 
and Phosphorylation of P300 ...................................................................................................... 45 
Figure 19: EMSA Result Showing Loss of HIF-1 DNA Binding Ability Following ALDOA 
Knockdown ................................................................................................................................. 47 
Figure 20: Proposed Mechanism of Glycolytic Regulation of HIF Activity ................................. 48 
Figure 21: Expression of Aldolase Relative to Sensitivity to Aldolase Knockdown  .................. 50 
Figure 22: Induction of Glycolytic Enzyme Expression in Panel of Cancer Cells Following 
Treatment with Hypoxia  ............................................................................................................. 51 
Figure 23: Inducible shALDOA Lines Established for Use in in vivo Experiments .................... 53 
Figure 24: Inducible ALDOA Knockdown Extends Survival in Murine Breast Cancer Model .... 54 
Figure 25: Inducible ALDOA Knockdown Reduces HIF Activity in Murine Breast Cancer Model
 .................................................................................................................................................... 55 
Figure 26: TCGA mRNA Expression Data Implicates ALDOA and ALDOC in Poor Patient 
Prognosis .................................................................................................................................... 57 
Figure 27: TCGA mRNA Expression Data Suggests ALDOB Should Not be Used for Patient 
Selection ..................................................................................................................................... 58 
Figure 28: Variable Expression of ALDOA in Tumors Predicts Median Survival ....................... 60 
Chapter 2: 
Figure 29: Computer Model of Aldolase A Active Site ............................................................... 67 
Figure 30: Optimization of in vitro Aldolase Activity Assay ........................................................ 71 
 xii 
Figure 31: Aldolase Activity Assay Result Using Lead Hit From Virtual Screen ........................ 73 
Figure 32: Optimization of Enzyme Concentration in High Throughput Small Molecule Screen 
 .................................................................................................................................................... 76 
Figure 33: Optimization of Substrate Concentration in High Throughput Small Molecule Screen 
 .................................................................................................................................................... 77 
Chapter 3: 
Figure 34: Time Dependent Inhibition of ALDOA Function Suggests Direct Protein Binding .... 82 
Figure 35: Cys239 and Cys289 Binding Appear Critical for Inhibition of ALDOA Function ....... 84 
Figure 36: TDZD-8 Inhibits Cancer Cell Proliferation and HIF-1 Activity in vitro ....................... 86 
Figure 37: TDZD-8 Inhibits Glycolytic Activity in vitro ................................................................ 87 
Figure 38: GC/MS Analysis Shows Inhibition TDZD-8 Inhibition of Glycolysis in vitro  ............. 88 
Figure 39: TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo ............................................. 90 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
List of Tables: 
Table 1: Small Molecule Collection Libraries and Corresponding Hit Rates .............................. 19 
Table 2: Glycolytic Enzyme Microarray Results in MIA PaCa-2 ................................................ 25 
Table 3: Secondary Validation of Genome Wide siRNA Screen Results ................................... 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
List of Abbreviations: 
°C Degrees Celsius  
2-DG 2-Deoxyglucose 
3-PG 3-Phosphoglycerate 
ADP Adenosine Diphosphate  
ALDOA Aldolase A 
ALDOB Aldolase B 
ALDOC Aldolase C 
AMPK 5' Adenosine Monophosphate-Activated Protein Kinase  
Arg Arginine 
Asp Aspartic Acid 
ATCC American Type Culture Collection  
ATP Adenosine Triphosphate  
BPG 1,3-Bisphosphoglycerate 
cAMP Cyclic Adenosine Monophosphate 
CBP CREB Binding Protein 
cLogP Partition Coefficient 
CMV Cytomegalovirus 
CO2 Carbon Dioxide 
COPB2 Coatomer Subunit Beta 2 
COX Cyclooxygenase 
CREB cAMP Response Element-Binding Protein 
DAP Dihydroxyacetone Phosphate 
DHAP Dihydroxyacetone Phosphate 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethylsulfoxide  
 xv 
DNA Deoxyribonucleic Acid  
Doxy Doxycycline 
DTT Dithiothreitol 
ECAR Extra Cellular Acidification Rate 
EDTA Ethylenediaminetetraacetic Acid 
EMSA Electrophoretic Mobility Shift Assay 
EP300 Adenovirus Early Region 1A Binding Protein p300 
Ex/Em Excitation / Emission 
F-6-P Fructose-6-Phosphate 
F-Actin Filamentous Actin 
FBP Fructose 1,6-Bisphosphate 
FBS Fetal Bovine Serum 
FDA Food and Drug Administration  
FDG-PET Fluorodeoxyglucose Positron Emission Tomography 
FI Fluorescence Intensity 
FIH Factor Inhibiting HIF 
G418 Geneticin Aminoglycoside Antibiotic 
GAP D-Glyceraldehyde-3-Phosphate 
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase 
GDH Glycerophosphate Dehydrogenase 
Glu Glutamic Acid 
GLUT-1 Glucose Transporter 1 
GOLD Genetic Optimization of Ligand Docking 
GP L-a-Glycerol Phosphate 
H2O Water 
HIF Hypoxia Inducible Factor 
 xvi 
HK Hexokinase 
HRE Hypoxia Responsive Element 
IgG Immunoglobulin G 
Kcat Number of substrate molecule each enzyme site converts to product per unit time 
KIF11 Kinesin Family Member 11 
KRAS Kirsten rat sarcoma 
Luc Luciferase 
M Molar  
MAPK Mitogen Activated Protein Kinase  
MgSO4 Magnesium Sulfate 
mM Millimolar  
mRNA Messenger Ribo Nucleic Acid 
Mut Mutant  
NAD Nicotinamide Adenine Dinucleotide (oxidized) 
NADH Nicotinamide Adenine Dinucleotide (reduced) 
ND Not Determined  
nM Nanomolar 
NOD-SCID Nonobese diabetic/severe combined immunodeficiency 
NSCLC Non-Small Cell Lung Cancer  
O2 Oxygen 
OCR Oxygen Consumption Rate 
P300 Adenovirus Early Region 1A Binding Protein p300 
P53 Tumor Protein p53 
PBS Phosphate Buffered Saline  
PCAF p300/CBP Associated Factor 
PDB Protein Data Bank 
 xvii 
PDK1 Pyruvate Dehydrogenase Lipoamide Kinase Isozyme 1, Mitochondrial 
PEP Phosphoenolpyruvate 
PGK1 Phosphoglycerate Kinase 1 
PGK2 Phosphoglycerate Kinase 2 
PH Domain Pleckstrin Homology Domain 
PI-3-K Phosphoinositide 3-kinase 
PLK1 Polo-Like Kinase1  
PTEN Phosphatase and Tensin Homolog 
PVDF Polyvinylidene Fluoride 
pVHL Von Hippel–Lindau Tumor Suppressor 
SAR Structure Activity Relationship 
SD Standard Deviation 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis  
Ser Serine 
shRNA Short-Hairpin Ribonucleic Acid  
siRNA Short-Interfering Ribonucleic Acid  
SSD Sum of Standard Deviations 
TCA Tricarboxylic Acid 
TCEP Tris(2-carboxyethyl)phosphine 
TCGA The Cancer Genome Atlas 
Thr Threonine  
VEGF Vascular Endothelial Growth Factor 
WASP Neuronal Wiskott–Aldrich Syndrome Protein 
WT Wild-Type  
Y Tyrosine  
µg Microgram  
 xviii 
µL Microliter 
µM Micromolar  
 1 
Introduction 
The targeted, preferential killing of cancer cells without non-specific toxicity to normal cells in 
the body is one of the most critical and difficult challenges in cancer chemotherapy. In order to 
create effective, non-toxic anticancer agents it is essential to gain a comprehensive 
understanding about the biological and biochemical processes that differ between these 
cancerous and normal cell populations. As technology and laboratory techniques have evolved 
over the years, tremendous progress has been achieved in the understanding of signaling 
molecules, specific genes, and proteins that are involved in cancer development and 
progression and with this progress has come a better appreciation for the need for these 
targeted therapies. With every discovery, however, comes a greater understanding about the 
complexities inherent to this disease. The high level of heterogeneity commonly found among 
the cells of a single tumor serves as a confounder as the wide range of genetic and epigenetic 
alterations can be so diverse that often the use of a single agent is impossible. For this reason, 
a range of target specific agents is often used in a cocktail of therapies to eliminate a wider 
range of malignant cells. Alternatively, the identification and subsequent exploitation of a 
fundamental difference between normal and cancer cells could lead to a level of therapeutic 
selectivity not previously described by allowing for remedial discrimination between malignant 
cells and those associated with a patient’s healthy tissue. 
 
Glycolysis and Cancer 
Aerobic glycolysis occurs by the Embden-Myerhoff-Parnas pathway, a series of cytoplasmic 
enzymatic steps converting glucose to pyruvate (generating 2 ATP per molecule of glucose). 
Pyruvate is metabolized by the mitochondrial tricarboxylic acid (TCA) cycle generating NADH, 
which fuels oxidative phosphorylation (thus producing 36 ATP for one molecule of glucose). In 
the first phase of glycolysis, molecular glucose undergoes a series of phosphorylations and 
isomerizations in preparation for its cleavage into two triose molecules. In the second phase of 
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glycolysis, glyceraldehyde 3-phosphate undergoes a series of energy-releasing processes to 
not only recover ATP that is invested early in the glycolytic process, thus providing chemical 
motive for further execution of the cascade, but also the generation of ATP through substrate-
level phosphorylation [5] (Figure 1).  Cancer cells rely heavily on glycolysis and, under aerobic 
conditions, it can provide over 60% of the cancer cells’ ATP compared to just 10% in normal 
cells. Warburg attributed this effect to defective mitochondrial oxidative phosphorylation in 
cancer cells [6], but subsequently it was shown that cancer cells have normal oxidative 
phosphorylation [2, 5, 7, 8].  More recently it has been shown that many actively dividing cells have 
high rates of glycolysis, and in most cases neither ATP nor NADH is limiting for cell growth [2].  It 
is now recognized that glycolysis is also a critical source of metabolic intermediates for the rapid 
synthesis of amino acids, nucleosides and lipids of the cellular biomass. High levels of aerobic 
glycolysis have been measured in a wide range of tumor types regardless of the tissue type 
from which they originated, as compared to their normal tissue counterparts which do not utilize 
aerobic glycolysis to satisfy their energy demands. This suggests that a characteristic of cancer 
cells, in combination with unrestrained growth, is that they revert to a metabolic phenotype, 
namely increased glycolysis, which provides proliferative advantages to rapidly dividing cells. 
This increased glycolysis in cancer cells is commonly referred to as the Warburg effect. 
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Figure 1.  The Glycolysis/HIF-1 Feed Forward Cycle in Cancer.  
 In upper glycolysis glucose is phosphorylated and isomerized to enable its cleavage into two trioses: 
1 – Glucose is phosphorylated at the 6 carbon through the use of ATP by the transferase class enzyme Hexokinase. 
This regulatory step is negatively regulated by the accumulation of the product, glucose-6-phosphate. 
2 – Glucose-6-phosphate is then converted to Fructose-6-phosphate (F-6-P) by Phosphoglucoisomerase 
3 – Fructose-6-phosphate is phosphorylated at the 1 carbon position, again through the use of ATP, by the 
transferase class enzyme Phosphofructokinase to yield Fructose-1,6,bisphosphate (FBP). This is often considered 
the primary control step in glycolysis as it is the committed step of the process due to its large delta G value. 
4 – FBP is then cleaved into two, three carbon molecules – Dihydroxyacetone phosphate (DHAP) and 
Glyceraldehyde-3-phosphate – by the lyase class enzyme Aldolase (Aldolase A [ALDOA]) is our primary 
target for inhibition shown in red).  
5 – DHAP produced in step 4 is converted to Glyceraldehyde-3-phosphate by Triose phosphate isomerase to satisfy 
the needs of the first step of lower glycolysis. 
In lower glycolysis, glyceraldehyde 3-phosphate undergoes two major energy-releasing electron rearrangements.  
6 – Glyceraldehyde-3-phosphate is phosphorylated at the 1 carbon position by Glyceraldehyde-3-phosphate 
dehydrogenase to yield 1,3-Bisphosoglycerate (BPG). 
7 – Phosphoglycerate kinase phosphorylates ADP to yield ATP and 3-phosphoglycerate (3-PG). 
8 – 3-PG is converted to 2-phosophoglycerate by Phosphoglycerate mutase. 
9 – 2-phosphoglycerate is then converted to phosphoenolpyruvate (PEP) by Enolase. H2O, potassium and 
magnesium are all released as a result. 
10 – Pyruvate kinase uses PEP to phosphorylate ADP and yield pyruvate. High levels of ATP, Acetyl-CoA, Alanine 
and cAMP can all negatively regulate this step. 
In parenthesis are number of isoenzymes, * indicates proteins induced by HIF-1.  
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Anaerobic Glycolysis 
In conditions of limited oxygen as found in most solid tumors (<1% O2 compared to 3–15% 
O2 found in normal tissues), pyruvate is converted to lactate by a process known as anaerobic 
glycolysis, and the lactate is then mostly secreted from the cell, although recent work suggests 
that in the heterogeneous tumor environment, some cells can use lactate as a source of fuel for 
mitochondrial oxidative phosphorylation [9].  There are 11 enzymatic steps to glycolysis with 40 
possible contributing isoenzymes. Glycolysis has to be supplemented by an increase in cellular 
glucose uptake through GLUT transporters that are also upregulated in cancer [10, 11], forming 
the basis for 18F-deoxyglucose positron emission tomography (FDG-PET) measurement of 
glucose uptake by patient tumors as an indicator of response to therapy [12, 13].  Activation of 
oncogenes, or loss of tumor suppressors can lead to upregulated glycolysis and glucose 
transport in cancer. These include PI-3-kinase, oncogenic protein tyrosine kinases that act 
through PI-3-kinase, and loss of the tumor suppressor PTEN, that all lead to downstream 
activation of AKT that maintains hexokinase function and localizes glucose transporters to the 
cell surface [14, 15].  Myc activates the transcription of several glycolytic enzymes [1, 16, 17] as does 
mutant KRAS [18, 19]. Inactivation of the tumor suppressor p53 causes a shift of energy 
metabolism to glycolysis through down regulation of mitochondrial respiration as a result of 
cytochrome C oxidase (COX) deficiency [20].  
 
Tumor Hypoxia as an Inducer of Glycolysis 
Hypoxic regions present in all solid tumors occur due to decreased blood flow and 
disorganized tumor vasculature and provide a stressful environment favoring tumor growth [21-23]. 
A cancer cell’s response to hypoxia is mediated by the hypoxia inducible transcription factors 
HIF-1 and 2 [24, 25], which together increase expression of numerous survival genes. Among 
them are genes that encode vascular endothelial growth factor (VEGF) (by HIF -1 and HIF-2 [26-
28]), glycolytic enzymes (by HIF-1 only [29]) and induction of the expression of GLUT-1 glucose 
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transporter [10, 17]. At the same time there is inhibition of mitochondrial aerobic respiration 
through induction of pyruvate-dehydrogenase kinase-1 (PDK1) [30]. Additionally, it has been 
shown that the ability of mutant KRAS, found in more than 97% of pancreatic cancer, to 
increase glycolysis is mediated through expression of HIF-1α, which is detectable in pancreatic 
cancer cell lines even under aerobic conditions [18, 19, 31].  
 
Inhibitors of glycolysis as cancer drugs 
A number of attempts have been made to develop inhibitors of enzymes of glycolysis as 
potential anticancer agents [32-37].  These have typically been simple small molecule analogs of 
substrates of glycolytic enzymes and include 2-deoxyglucose a competitive inhibitor of glucose 
utilization [38, 39] which has, historically, shown minimal clinical activity at doses that can be safely 
administered to patients [40], 5-thioglucose and 3-bromopyruvate as hexokinase (HK) inhibitors 
[41, 42] when infused in rabbits are severely hepatotoxic [43], and dichloroacetate, an inhibitor of 
PDK1 [44] which is known to cause toxic neuropathy in humans [45]. Overall the use of small 
molecule substrate analogs to inhibit glycolysis has yielded disappointing clinical effects, and in 
many cases considerable toxicity.  
 
HIF-1 as a Tumor Survival Factor and Cancer Drug Target    
HIF-1 and 2 are critical mediators of the hypoxic response and transactivate a large number 
of genes promoting a wide range of factors associated with cancer progression including 
angiogenesis, anaerobic metabolism and resistance to apoptosis [46] with HIF-1α preferentially 
inducing glycolytic enzyme genes [24, 29]. HIF-1 is a heterodimer comprised of an oxygen labile 
HIF-α subunit and a stable HIF-1β subunit. Under aerobic conditions HIF-1α is hydroxylated by 
the prolyl hydroxylase proteins and subsequently ubiquitinated by the von Hippel Lindau protein 
(pVHL) and targeted for proteasomal degradation [47]. During hypoxia, pVHL binding is 
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abrogated due to the lack of this hydroxylation. The resulting stabilization of HIF-1α causes its 
translocation to the nucleus where it heterodimerizes with HIF-1β and binds to a conserved 
DNA sequence known as the hypoxia responsive element (HRE), thus transactivating a variety 
of hypoxia-responsive genes [48].  Elevated levels of tumor HIF-1α have been associated with 
poor patient survival in multiple tumor types [49]. HIF-1α is thus an attractive target for cancer 
drug development and a number of inhibitors have been reported [50]. Recently the clinical trial of 
a first generation HIF-1α inhibitor, PX-478 was reported with promising results establishing the 
validity of HIF-1α as a drug target [51]. The mechanism by which PX-478 inhibits HIF-1α remains 
unclear and the off target side effects of PX-478 will likely limit its future development. However, 
HIF-1α remains a promising target for drug development and second-generation inhibitors with 
defined mechanisms of action and low toxicity are needed. 
 
ALDOA as a Cancer Drug Target 
It is known that malignant transformation results in a significant change in the expression of 
glycolytic isoenzymes and favors those isoenzymes that facilitate survival and uncontrolled 
proliferation. It has been found that the expression of ALDOA is significantly elevated relative to 
the two other isoforms, ALDOB and ALDOC, in a wide variety of human tumor types including 
pancreatic cancer [29]. ALDOA is also highly expressed in developing embryos suggesting it is 
adapted to the metabolic requirements of rapid cell proliferation [52, 53]. ALDOA has also been 
shown to have a kcat that is significantly higher than that of the other ALDO isoenzymes [54, 55]. 
Based on these findings it has been suggested that ALDOA could serve as a cancer drug target 
for inhibiting glycolysis [33, 56]. We have now shown a novel finding that ALDOA is the most 
important of the 40 isoenzymes of glycolysis responsible for maintaining HIF-1 activity. It is a 
doubly attractive target based on the finding that its inhibition leads to both an inherent reduction 
in cancer cell energy metabolism and HIF-1 activity. Aldolases have also been reported to bind 
to a number of non-glycolytic proteins including F-actin [57], WASP and N-WASP, activators of 
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Arp2/3 and actin polymerization [58] and the PH domain of phospholipase D2 [59]. Although the 
significance of this binding is not clear, the observations have also led to the suggestion that 
Aldolases could be a target for inhibiting cancer growth [60].  
Summary 
In this study, the identification of a novel feed-forward cycle of increased HIF-1α and 
increased glycolysis that is critical for tumor growth and survival, is paired with an understanding 
that the inhibition of the glycolysis/HIF-1 cycle is selective for hypoxic tumor cells due to the fact 
that normal aerobic dividing cells, despite using aerobic glycolysis do not express HIF-1. 
Inhibiting this cycle, thus, provides a novel way to target human malignancies. In pancreatic 
cancer where the glycolysis/HIF-1 cycle appears to be particularly prominent, the key activating 
event may be increased HIF-1α by mut-KRAS even in hypoxic conditions. This may be why 
KRAS signaling is significantly correlated with glycolysis in pancreatic cancer [61, 62]. Considering 
this fact and taking into account that it is overexpressed in pancreatic cancer and strongly 
associated with decreased patient survival, we have identified and validated the glycolysis 
enzyme ALDOA as a critical step in the glycolysis/HIF-1 cycle. By using ALDOA as a target for 
the design of pharmacological probes, we are able to attack, at the same time with a single 
agent, two critical cancer survival mechanisms: glycolysis and angiogenesis. ALDOA has a 
known crystal structure which allowed us to use molecular modeling for lead optimization, and 
co-crystallography for validation of ALDOA-inhibitor leads. Through the combination of virtual 
screening, high-throughput consideration of large small molecule libraries and subsequent 
validation of lead compounds in biological assays, we have identified low micromolar affinity 
inhibitors of ALDOA as tool compounds and as potential leads for preclinical development as 
novel anticancer agents. Further, we have identified a potential mechanism for inhibition of 
ALDOA leading to decreased HIF-1 activity through the AMPK inhibition of the HIF-1 co-
activator p-300 allowing for the combination of novel target identification, elucidation of 
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biological mechanisms responsible for the critical nature of the target in the progression of 
human cancer, discovery of probe inhibitors and validation of their efficacy using both in vitro 
biochemical and in vivo anti-tumor experiments. 
 
Materials and Methods 
Cells and Culture Conditions  
MIA PaCa-2, MDA-MB-231, and PANC1 cell lines were obtained from the American Type 
Culture Collection (ATCC) and grown in DMEM media; HT-29 cells were obtained from ATCC 
and cultured in McCoy’s 5A media. DNA fingerprinting was conducted by the University of 
Texas M.D. Anderson Cancer Center Characterized Cell Line Core Service at the same time as 
total protein lysate preparation in order to confirm the identities of cells used in all experiments. 
All cell lines were routinely tested to be mycoplasma free using the e-Myco kit (Boca Scientific).  
 
Creation of Stable and Inducible Cell Lines  
Following karyotype analysis, a 5X HRE repeat (hypoxia response element) sequence from 
the VEGF and EPO genes was cloned in front of firefly luciferase in the pGL3 Basic Vector. This 
HRE/luciferase sequence was then sub-cloned into the pcDNA3.1 vector with Neomycin 
resistance. The resulting plasmid was transfected into MIA PaCa-2 and PANC1 pancreatic 
carcinoma, MDA-MB-231 breast adenocarcinoma, and HT-29 colorectal adenocarcinoma cells 
and stable clones selected following long term culture in DMEM 10% FBS with G418 selective 
pressure using 300 µg/mL Geneticin (Invitrogen).The reporter plasmid was a gift of Dr. R. Gillies 
(Moffitt Cancer Center, Tampa, FL). Following selection, pools of stably transfected cells were 
generated and frozen for later use.  
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For conditional Aldolase A knockdown in an in vivo murine model, four sequences predicted 
to target ALDOA gene expression were selected from the Thermo Scientific Dharmacon shRNA 
library and each was inserted into a TRIPZ doxycycline inducible lentiviral vector (Open 
Biosystems). Each of the four HRE luciferase lines described above was transduced with 
shALDOA-expressing lentivirus, and stable lines were selected in puromycin in 96-well plates 
with one cell per well to generate clonal populations. After puromycin and G418-resistant clones 
were selected, shALDOA expression was induced using doxycycline in both normoxia and 
hypoxia (1% O2) to assess ALDOA knockdown. 
 
siRNA Screening  
Cells underwent two consecutive passages in the absence of G418 selection before 
confirmation that the cells were mycoplasma negative. Optimization of ideal transfection reagent 
and reagent concentration was carried out using high-throughput optimization methods for 
reverse transfection (Figure 2). In the course of this process, 8 transfection reagents from 
various manufacturers (DharmaFECT 1, 2, 3, and 4 [Dharmacon], XtremeGENE [Roche], 
Lipofectamine RNAiMAX [Invitrogen], HiPerfect [Qiagen], or siPort NeoFX [Thermo Fisher 
Scientific]) were used in a range of concentrations per well and paired with one of nine negative 
(siGenome Scrambled Non-targeting control 1, 2, 3, 4 or 5 or siOnTargetPlus Non-targeting 
control 1, 2, 3, or 4 [Dharmacon]) or one of four positive controls (siPLK1 an inhibitor of the 
G2/M transition [63], siTOX an inducer of the interferon response [64], siCOPB2 an inhibitor of 
Golgi budding and vesicular trafficking [65], or siKIF11 an inhibitor of mitotic spindle formation 
[66]). Optimal combinations were identified by calculation of z’-factor ultimately yielding the 
combination of least toxic and most efficient transfection reagent, least toxic negative control 
siRNA and most effective positive control siRNA per cell line.  
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Figure 2.  siRNA Transfection Optimization Format  
The combination of 8 transfection reagents with nine positive and four negative control siRNAs allows for the 
identification of the optimal combination of reagents and controls per cell line when the z’-factor criteria was satisfied 
per the following equation: 
 
 Z’-factor = 1-(3*(SSD/(Range))) 
 SSD – sum of standard deviations in negative control and positive controls samples 
 Range – negative control average – positive control average 
 
If the end value was greater than .7, the assay was considered robust enough to continue. 
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Following optimization, parallel screens were then carried out with a genome wide siRNA 
library (Dharmacon) in one of two different levels of oxygenation: normoxia or hypoxia. 
Optimization of cell number and O2 level was conducted in order to identify the ideal conditions 
for hypoxia related experiments (Figure 3).  To this end, 60–70% confluent cells were cultured 
in a hypoxia chamber (InVIVO2 400, Ruskinn) flushed with 1% O2 and 5% CO2 with balance of 
94% nitrogen at 37  °C for 16 hours following 48 hours of transfection in air. Control cells were 
placed in a 5% CO2 and 95% air incubator (20% O2) at 37  °C for the duration of the experiment. 
All experiments were conducted in 384 well, white, clear-bottom, tissue culture treated plates 
(Falcon) in which 10 µl of 1x siRNA buffer containing 200 nM siRNA was complexed with 10 µl 
of OptiMEM transfection media containing 0.07 µl of XtremeGENE (Roche) for 30 minutes prior 
to the addition of a mixture of 30 µl of complete DMEM media (10% FBS) and 2000 cells. At the 
completion of experiments, cell viability was first measured using the cell proliferation reagent 
WST-1 (Roche) followed by the washing of the wells with PBS and subsequent analysis of 
HRE-luciferase expression and activity using an in-house luciferase assay buffer containing 25 
mM Tricine, 0.5 mM EDTA-Na2, 0.54 mM Na-triphosphate, 16.3 mM MgSO4*7 H2O, 0.3% 
Triton X-100, 0.1% DTT, 10 mM ATP, and 2.7 mM Coenzyme A adjusted to pH 7.8 to yield a 
combined viability and HRE activity reading. 
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Figure 3.  Optimization of O2 Conditions Based on Growth Rate and HRE-luciferase Activity in Hypoxia Based 
Experiments  
Growth rate (based on cell number) and HRE-luciferase activity was measured at 12 hour time points in order to 
identify optimal oxygen concentration conditions and duration of the exposure to hypoxia in order to have the highest 
possible baseline HRE-activity during the high throughput siRNA screen to find inhibitors of HIF-1 transcriptional 
activity. Values are the mean of 6 determinations. Bars are S.D. 
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Individual siRNA Transfection 
After identifying initial glycolysis genetic hits, follow-up work in each of the 3 additional cell 
lines listed was conducted by de-convoluting pooled siRNA for selected targets from an 
alternative supplier for additional validation purposes. For transfection in a six well plate format, 
300 µl of 1x siRNA buffer containing 200 nM siRNA was added to each well followed by 300 µl 
of OptiMEM with 2.5 µl of either DharmaFECT 4 (for MDA-MB-231 and PANC1 transfections), 
DharmaFECT 1 (for HT-29) or XtremeGENE (for MIA PaCa-2). Following 30 minutes of 
incubation at room temperature to allow for transfection reagent-siRNA complexing, 900 µl of 
complete media containing 100,000 cells was added per well yielding a final screening 
concentration of 40 nM siRNA. Per well siALDOA SMARTpool (Dharmacon, M-010376-01), 
individual siALDOA siRNAs (Qiagen GS226), siPGK1 SMARTpool (Dharmacon, M-006767-01), 
individual siPGK1 siRNAs (Qiagen, GS5230), siPGK2 SMARTpool (Dharmacon, M-006768-02), 
or individual siPGK2 siRNAs (Qiagen, GS5232) was added and knockdown efficiency was 
determined by Western blotting of cell lysates 96 hours post transfection. Dharmacon 
SMARTpool siRNAs for HIF-1α, AMPK, EP300, PLK-1 or the On-Target-Plus non-targeting pool 
#4 (OTP4) were included as controls. Total siRNA concentration was kept at 40 nM when 
siRNA combinations were used.  
 
Immunoblots and Immunoprecipitations  
Cells were washed twice with pre-chilled, ice-cold PBS before adding ice-cold lysis buffer 
containing 50 mmol/L HEPES (pH 7.5), 50 mmol/L NaCl, 0.2 mmol/L NaF, 0.2 mmol/L sodium 
orthovanadate, 1 mmol/L phenylmethylsulfonyl fluoride, 20 µg/mL aprotinin, 20 µg/mL leupeptin, 
1% NP40, and 0.25% sodium deoxycholate. Following scraping, samples were vortexed 
frequently on ice for 20 minutes, followed by microcentrifugation at 14,000 rpm for 10 minutes. 
Cleared supernatants were collected, followed by protein quantification using the BCA reaction 
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kit (Pierce Biotechnology, Inc.) and 50 µg of cell lysate protein were boiled for 5 min with 
denaturing buffer containing 0.25 mol/L Tris (pH 6.8), 35% glycerol, 8% SDS, and 10% 2- 
mercaptoethanol, loaded on a 10% acrylamide/bisacrylamide gel, and separated by 
electrophoresis at 90 V for 1 hour and 20 minutes. Proteins were electrophoretically transferred 
to a methanol activated polyvinylidene fluoride (PVDF) membrane; pre-incubated with a 
blocking buffer of 5% milk; and incubated overnight with anti–phosphorylated Thr172 – AMPK or 
anti-AMPK (Cell Signaling 1:1000), anti-HIF-1α (BD Biosciences 1:500), anti-Aldolase A 
(AbNova 1:500), anti-Aldolase B or anti-Aldolase C (Novus Biologicals 1:1000), anti-
phosphorylated Ser89-EP300 or anti-EP300 (Santa Cruz Biotechnology 1:1000) or anti-β-actin 
(Santa Cruz Biotechnology 1:2000). Donkey anti-rabbit, sheep anti-mouse (GE Healthcare), or 
donkey anti-goat (Santa Cruz Biotechnology) IgG horseradish peroxidase-coupled secondary 
antibody was used for detection where appropriate. Band density was measured using the 
densitometry functionality found within the Image-J open source image analysis program 
following ECL mediated image development on either Kodak X-Omat Blue ML films (Eastman 
Kodak) or the FluorChem M Imaging Platform (Protein Simple). 
 
Determination of Cellular ATP Concentration   
Cellular ATP was measured using an ATP Assay Kit (Abcam) according to the 
manufacturer’s protocol and quantified by both colorimetric (λmax = 570 nm) and fluorometric 
(Ex/Em = 535/587 nm) methods, 96 hours post siRNA-transfection. Each experiment was 
performed in both biological and technical triplicates. 
 
Xenograft Analysis   
Approximately 107 MDA-MB-231 HRE cells, MDA-MB-231 cells harboring shALDOA clones 
8.8 and 9.7, and MDA-MB-231 HRE empty vector cells, all in log cell growth, were suspended 
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each in 0.2 mL PBS and injected subcutaneously into the mammary fat pads of female NOD-
SCID mice. Groups contained five mice each. When the tumors reached 250 mm3, chow 
containing doxycycline was substituted for control feed (Harlan Laboratories) in test groups.  An 
additional group of five mice was fed doxycycline containing chow for one week prior to injection 
of the inducible cells to measure the possible inhibitory effect on initial tumorigenesis.  Mice 
were euthanized when they became clinically moribund associated with the metastatic spread of 
the MDA-MB-231 tumor to liver and lung.   Animal studies were approved by SBPMRI’s Animal 
Care and Use Committee. 
 
Molecular modeling  
Target Receptor and Chemical Database selection 
The crystal structure of Aldolase was obtained from the Protein Data Bank [67] (4ALD) and 
considered as the basis for virtual screening [68]. For the ligand set used in these virtual screens, 
we selected the 10,000 compound Myria Screen chemical library. 
 
Virtual Screening 
The virtual screens were performed using the GOLD (Genetic Optimization for Ligand 
Docking) software from CCDC [69]. GoldScore was chosen as the fitness function, and 29 
residues within 6Å of 2FP (fructose 1,6-bisphosphate) were selected as defining the binding 
site.  
Two successive GOLD screens were carried out: the first screen docked the entire 
MyriaScreen ligand set into a rigid structure in which no considerations were made as to 
flexibility of the structure. The resulting top 2000 ligands were then clustered based on structural 
MACCS (Molecular ACCess System) fingerprints using MOE fingerprint clustering. The second 
screen considered only the top 60 unique scoring ligands allowing for flexible side chains. Using 
the Tanimoto coefficient with chemical similarity and overlap considerations set to 60%, cluster 
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centers were retained. The resulting 60 unique ligands from this clustering were then minimized 
in MOE, and screened a second time in GOLD with full flexibility considerations made for the 
following Aldolase residues: Asp33, Ser38, Lys146, Arg148, Glu187, and Lys229. These 
residues were selected as flexible based on location relative to the binding site and propensity 
to form favorable interactions with the natural substrate, 2FP. 
The results from the second screen were then individually visualized (using PyMOL) in their 
docked conformation (protein-ligand complex). Two main criterions were considered in the final 
selection process. First was the resulting orientation and configuration within the protein 
structure. We considered interactions that would increase the binding affinity (e.g. hydrogen 
bonds, static and aromatic effects). The second consideration was the distinctiveness in the 
molecular scaffold when compared to the other ligands at this stage. We placed the ligands into 
“classes” based upon the individuality of their underlying scaffold and how this scaffold was 
oriented in the binding site. Ligands that shared a similar scaffold and orientation were 
considered to be in the same class. Based on the combination of the two criteria, 22 ligands in 
total were recommended to be tested for biological activity. 
 
Aldolase Enzymatic Activity Assay  
A 96 well plate assay based on conversion of fructose 1,6-bisphosphate (F-1,6-BP) into 
glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) measured in a 
coupled reaction with GAP dehydrogenase by the oxidation of NADH to NAD was used to 
measure the effect on Aldolase A cleavage activity using an adapted method previously 
described [70]. All enzymatic assays were conducted at 22º C in a final volume of 100 µl following 
the addition of recombinant Aldolase A protein (Novus Biologicals) to a reaction mixture 
containing substrate, 0.15 mM NADH, 50 mM Tris-acetate, 10 mM EDTA (pH 7.6), 100 mg/ml 
bovine serum albumin, and 2 mg/ml α-glycerophosphate dehydrogenase/triose phosphate 
isomerase. Enzymatic activity was measured by endpoint assay at 364 nm sampling at 30 
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second intervals. Initial attempts to verify ability of previously selected compounds from virtual 
screening methods to inhibit Aldolase activity was monitored by following this NADH-dependent 
coupled reaction at 340 nm proved to be incompatible with high throughput screening due to 
spectroscopic interference at 340 nm by compounds typically found in screening collections. To 
address this challenge we developed a robust fluorescence-based assay for ALDOA (Figure 4) 
and screened a collection of >65,000 compounds (Table 1) in 384-well format, identifying 
approximately 20 novel inhibitors with EC50‘s in the range of 1-20 µM, whose affinity compare 
favorably to that of Fru-1,6-P2 using the protocol outlined in Figure 5. 
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Figure 4.  Optimization of Fluorescence-based NADH Oxidation HTS Aldolase Assay  
Glyceraldehyde-3-phosphate dehydrogenase converts glyceraldehyde-3-phosphate (G-3-P) to 1,3-
bisphosphoglycerate (1,3-BGP) through oxidative phosphorylation. NAD+ is reduced to NADH when a phosphate 
group is exchanged for a hydrogen on the carbonyl carbon of G-3-P thus converting G-3-P to 1,3-BGP. This assay 
uses glycerophosphate dehydrogenase to catalyze the conversion of dihydroxyacetone phosphate (the product of the 
ALDOA catalyzed reaction) to glyceraldehyde-3 phosphate in an NADH-dependent manner.  Thus, the rate of change 
of fluorescence intensity is used to indirectly calculate the activity of ALDOA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:	  
ADL	  (Aldolase)	  
GDH	  (Glycerophosphate	  Dehydrogenase)	  
F-­‐1,6-­‐DP	  (Fructose-­‐1,6-­‐diphosphate)	  
DAP	  (Dihydroxyacetone	  phosphate)	  
GAP	  (D-­‐Glyceraldehyde-­‐3-­‐phosphate)	  
GP	  (L-­‐a-­‐Glycerol	  phosphate)	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Compound Collection Total Compounds # of Hits Hit Rate 
Kinase focused 652 14 2.15 
NIH clinical 674 4 0.59 
Lopac 1,280 4 0.31 
Spectrum 2,000 15 0.75 
Academic (UT Austin/Kansas) 2,100 7 0.33 
NCI Diversity 2,537 12 0.47 
Chembridge Fragment 4,000 69 1.73 
Chembridge KINASet 11,250 94 0.84 
Chemdiv Fragment 12,800 70 0.55 
Chemdiv Diversity 14,243 132 0.93 
Maybridge Diversity 14,400 219 1.52 
Total 65,936 640 0.97 
 
Table 1.  Commercial and Academic Small Molecule Collections and Corresponding Hit Rates in High 
Throughput Small Molecule Inhibitor Screen  
Commercial and academic collections used in the high throughput small molecule inhibitor screen representing 
structurally diverse sets of compounds known to be biologically active and drug like: 
 
• The kinase focused library was custom-selected by screening group at UT Austin and is comprised of 600+ 
compounds known to have inhibitory effects against more than 100 kinases. 
• The Evotec NIH clinical collection is part of the NIH Molecular Libraries Small Molecule Repository which 
distributes samples for high throughput biological screening. 
• Lopac1280 from Sigma-Aldrich is a collection of 1280 pharmacologically active compounds including 
marketed drugs 
• The Spectrum collection uniquely offers a combination of drug components, natural products, and other 
bioactive components which have been dropped from development for toxicological or other reasons. 
• Academic collections were a result of deposited samples composed of unique molecules with diverse 
pharmacophores by chemists at both the University of Texas at Austin and University of Kansas. 
• The NCI diversity set   is a small library, ideal for beginning a screening campaign, consisting of a collection 
of chemically diverse synthetic small molecules selected from the full NCI screening collection to allow 
users to focus their cancer screening efforts on a small scale. 
• The Chembridge Fragment and Kinase Sets are customizable collections of fragment compounds chosen 
based on satisfaction of the Astex Rule of Three  in which the compound’s molecular weight is <300, the 
number of hydrogen bond donors is ≤3, the number of hydrogen bond acceptors is ≤3 and ClogP is ≤3 [71] 
and in silico validated pharmacophores that may interact with ATP ligand sites of kinases. 
• Fragments in the Chemdiv collection contain only C, H, N, O, S, P, F, Cl and Br atoms, are highly water 
soluble and feature diversity, low structural complexity and a high level of drug-likeness. 
• Additional diversity found in the Maybridge collection has a high rate (95%+) of satisfying Lipinski’s Rule of 
5. 
 
Hits were selected based on inhibition of Aldolase enzymatic activity by at least 30% relative to negative controls 
using a modified Elite NADH fluorescent probe coupled enzymatic activity assay. 
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Figure 5.  High Throughput Small Molecule Screening Protocol: 
1. Prepare a 2x Aldolase A mixture (5 nM) in 1X assay buffer (1x PBS 0.01% TritonX-100, 0.1% BSA) and 
dispense 4 µl to the assay plate (AP) 
2. Spin plate at 800 RPM for 1 minute to ensure that entire volume is at the bottom of each well 
3. Dispense 30 µl water into dilution plate (DP) and add 0.6 µl of 10 mM compound solutions to make a 200 
µM (4x) compound stock solution. 
4. Directly transfer 2 µl of the compound stock to the assay plate. 
5. Spin plate at 800 RPM for 1 minute, seal, and incubate at room temperature for 1 hour. 
6. Prepare 4x substrate mixture (F(1,6)BP, Glyceraldehyde Dehydrogenase and NADH) in 2x assay buffer. 
7. Dispense 2 µl of substrate mixture into assay plate. 
8. Spin plate at 800 RPM for 1 minute, seal, shake plates at 250 RPM for 5 minutes followed by an additional 
800 RPM spin. 
9. Incubate plates for 40 minutes at room temperature. 
10. Mix NADH recycling enzyme with NADH assay buffer from the Elite NADH assay kit and dispense 8 µl into 
assay plate. 
11. Spin plate at 800 RPM for 1 minute, seal, and incubate for 1 hour at room temperature. 
12. Read fluorescence intensity with excitation/emission spectra at 540/590 nm per the manufacturer’s 
instructions. 
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Measurement of Cellular Glycolysis  
Glycolytic function was assessed by quantifying the rate of lactate formation using the 
Seahorse Bioscience XF96e platform (Seahorse Bioscience) and the XF Glycolysis Stress Test 
Assay according to the manufacturer’s protocol. Historic studies of cellular function have been 
performed on monolayer cultures adherent to rigid substrates. Cells within a human tissue, 
however, are typically encased within a tightly packed mass of cells in which connections with 
many neighbors and with extracellular matrix components occur.  Cells within a 3D environment 
experience fundamentally different growth conditions compared to those experienced by cells 
grown in monolayer culture. In order to measure glycolysis under hypoxic, physiologically 
relevant conditions, a modified hanging drop tissue culture method [72] was used to evaluate 3-
dimensional spheroids of PANC-1 HRE cells transduced with shALDOA constructs.  On the lid 
of a 100 mm2 tissue culture dish, 20 10 µl droplets of complete media containing 10,000 +/- 
2500 cells (depending on cell line) were arrayed using a multi-channel pipette. The bottom of 
the dish was filled with 5 ml of PBS to act as a hydration chamber to prevent evaporation of 
volume from the hanging drop during 3 day incubation times.  Three days after seeding cells 
and 24 hours before running the XF Glycolysis Stress Test, shALDOA expression was induced 
with 400 ng/ml doxycycline. A final volume of 175 µl of pre-conditioned assay medium 
containing 18 spheroids was added to each well of a test plate and incubated at 37ºC in a CO2-
free incubator until the experiment was initiated. The use of this hanging drop method allowed 
for the generation of spheroids ranging in size from 300-500 µm which exhibited a hypoxic core 
based on analysis with a fluorescent LOX-1 hypoxia probe (SCIVAX USA, Inc) without the need 
for hypoxic gassing conditions. 
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Crystallization and Structure Solution 
Screens for the identification of optimized crystallization conditions were performed using a 
96-reagent crystallization screen Index (Hampton Research) and a Phoenix robotic drop 
dispenser (Art Robbins Instruments). Using the sitting drop vapor diffusion method, ALDOA was 
co-crystallized with inhibitor naphthalene-2,6-diyl bis(dihydrogen phosphate) (NBP). Drops (0.4 
µl each) containing 0.2 µl  of the protein solution (18 mg/ml ALDOA, 3 mM NBP, 15 mM TRIS 
buffer pH 7.6, 150 mM NaCl, 0.7 mM TCEP), and 0.2 µl of the crystallization buffer (25% PEG 
3350, HEPES buffer pH 7.0), were equilibrated against the crystallization buffer at 23°C. 
Crystals grew within 2 weeks measuring 0.20x0.06x0.06 mm3.  To measure the binding capacity 
of a lead compound found in high throughput screens of chemical libraries, a 4-benzyl-2-methyl-
1,2,4-thiadiazolidine-3,5-dione (TDZD-8) (MedKoo Biosciences) complex was made by soaking 
preformed NBP co-crystals in PEG 3350 (23% w/v) containing 1.5 mM TDZD-8 for 4 h at 23°C. 
Crystals were flash-frozen in liquid nitrogen after adding 15% PEG 400 as a cryoprotectant.  
Diffraction data were collected at the Stanford Synchrotron Radiation Laboratory (SSRL), 
beamline 12-2, and processed using AUTOXDS [73] and the CCP4i program suite [74]. The 
structures were solved using the molecular replacement program PHASER [75] and the ALDOA 
structure (PDB ID: 1ALD) as the search model. Refinement and manual rebuilding were done 
with REFMAC5 [76] and COOT [77]. The final model is refined at 2.5 Å resolution to an R-factor of 
20% (RFREE = 24%).  
 
The Cancer Genome Atlas Data Analysis 
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOA, 
ALDOB and ALDOC mRNA in The Cancer Genome Atlas (TCGA) PANCAN datasets was 
carried out using publicly available data. Survival data was corrected for tumor type, patient age 
and patient sex. In this way, TCGA data for mRNA expression as it relates to patient survival 
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was used to analyze differences between paired samples using the student’s t-test in addition to 
calculation of Pearson’s correlation and linear regression analysis.  
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Glycolytic Enzymes Regulate HIF-1α Activity 
In order to identify genes potentially regulating cellular HIF activity we conducted a genome-
wide siRNA screen using MIA PaCa-2 pancreatic cancer cells with a stably integrated 5x 
HRE/promoter-luciferase (luc) reporter to search for genes that, when silenced would inhibit HIF 
activity. It is important to note that the reporter cannot distinguish between HIF-1 and HIF-2 
activity which was made evident by results that will be discussed later. That screen, which was 
conducted using a genome wide siRNA library (Dharmacon), identified several glycolysis-
related factors. This was an unexpected finding given that while it is known that expression of a 
number of glycolysis genes are up-regulated by HIF-1 [4, 27], although not by HIF-2 [27], the fact 
that glycolysis had any regulatory effect on HIF transcriptional activity had not been reported. 
Identification of various genes in the pathway opened an interesting new avenue in an early 
novel therapy design effort so the up-regulation of potential targets as a result of HIF-1 activity 
was confirmed in MIA PaCa-2 cells using small scale, directed mRNA expression profiling. By 
limiting a typical class discovery experiment in which thousands of possible gene expression 
levels can be assessed [78] and analyzing only glycolytic genes, a clear pattern of reliance on 
HIF-1 activity for expression during hypoxic stress was identified (Table 2).   
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Gene: Fold change hypoxia: Fold change siHIF-1α: 
HK1 2.611 0.491 
HK2 5.308 0.426 
HK3 No Change No Change 
GPI 2.108 0.675 
PFKM 0.701 1.250 
PFKL No Change No Change 
PFKP No Change No Change 
PFKFB1 No Change No Change 
PFKFB2 No Change No Change 
PFKFB3 No Change No Change 
PFKFB4 No Change No Change 
ALDOA 2.319 0.716 
ALDOB No Change No Change 
ALDOC 14.840 0.333 
TPI1 2.299 0.533 
GAPDH 2.051 0.658 
PGK1 5.473 0.378 
PGK2 7.947 0.259 
PGAM1 2.287 0.649 
PGAM2 No Change No Change 
BPGM 0.588 1.505 
ENO1 2.351 0.573 
ENO2 4.807 0.277 
ENO3 1.115 1.750 
PKLR No Change No Change 
PKM2 1.892 0.855 
 
Table 2. HIF-1 Knockdown Inhibits Genes Encoding Glycolytic Enzymes in Hypoxic MIA PaCa-2 Pancreatic 
Cancer Cells.  
Thirty genes encoding glycolytic enzyme isoforms were selected for validation and investigation based on results 
from the genome-wide siRNA screen used to identify inhibitors of cellular HIF-1α activity. Through the use of 
microarray methodologies, we measured fold-change in expression of glycolytic enzymes following control siRNA 
transfection and exposure to hypoxia (siControl hypoxia/siControl normoxia) or fold-change following HIF-1α 
knockdown (siHIF-1α hypoxia/siControl hypoxia).  
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The combination of a clear pattern of HIF-1 activity inhibition with siRNA knockdown of glycolytic 
gene expression as observed in the primary, genome-wide screen and the heavy reliance on 
HIF-1 expression and activity for glycolysis gene expression suggested the existence of a 
previously undescribed glycolysis/HIF-1 feed forward loop.  To test this possibility we used an 
isolated panel of siRNAs specific to 30 glycolysis genes and their isoforms (including pyruvate 
dehydrogenase, which is responsible for post-glycolytic pyruvate modification in mitochondria) 
and measured HRE-luciferase activity and cell viability in the same well. Using MIA PaCa-2 
pancreatic cancer cells, we found compelling evidence that glycolytic enzyme activity is critical 
for the normal functionality of HIF-1, further confirming the observations that we made following 
the primary screen (Figure 6). Similar results were obtained using PANC-1 HRE-luc pancreatic, 
MDA-MB-231 HRE-luc metastatic breast and HT-29 HRE-luc colon cancer cell lines which had 
been stably transfected with the same HRE-luc reporter used for the MIA PaCa-2 cells in the 
primary screen (Figures 7 - 9). Despite marked changes in HIF-1 activity in gene knockdown 
events across many of the siRNAs included in the panel, cell growth inhibition was rarely more 
than 25% except in the case of ALDOA knockdown. The decrease in normalized HRE-luc 
activity (luciferase activity normalized to effects seen on cell viability to remove cell death or 
growth inhibition as a possible false positive for inhibition of HIF-1 activity) in all lines followed 
the same pattern as the greatest decrease was observed following ALDOA inhibition, followed 
closely by knockdown of PGK1 (phosphoglycerate kinase 1) or its isoform PGK2 
(phosphoglycerate kinase 2) depending on the cell line. It is for this reason that ALDOA was 
selected for further development of novel, dual glycolysis/HIF inhibitors. 
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Figure 6. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in MIA PaCa-2 HRE-luc Cells.  
Thirty genes encoding glycolytic enzyme isoforms were selected for validation from a genome-wide siRNA screen for 
inhibitors of cellular HIF-1 activity. HIF-1 activity was measured using MIA PaCa-2 pancreatic cancer cells stably 
transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after 
24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of 
viability reagent.  Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as 
controls.  Bars represent S.D. of 3 studies.   
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Figure 7. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in PANC-1 HRE-luc Cells.  
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA 
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used 
for primary screening purposes. HIF-1 activity was measured using PANC-1 pancreatic cancer cells stably 
transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after 
24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of 
viability reagent.  Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as 
controls.  Bars represent S.D. of 3 studies. 
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Figure 8. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in MDA-MB-231 HRE-luc Cells.  
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA 
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used 
for primary screening purposes. HIF-1 activity was measured using MDA-MB-231 metastatic breast cancer cells 
stably transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and 
after 24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of 
viability reagent.  Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as 
controls.  Bars represent S.D. of 3 studies. 
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Figure 9. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in HT-29 HRE-luc Cells.  
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA 
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used 
for primary screening purposes. HIF-1 activity was measured using HT-29 colon cancer cells stably transfected with a 
constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after 24 hr hypoxia (1% 
oxygen). Values were then normalized to cell viability in the same wells following aspiration of viability reagent.  
Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as controls.  Bars 
represent S.D. of 3 studies. 
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Similar inhibitory effects were observed in the 786-0 renal adenocarcinoma cell line stably 
transfected with the same HRE-luciferase promoter, suggesting that regulation of HIF activity is 
not limited to HIF-1, as these cells express HIF-2 exclusively. Furthermore, differences with this 
cell line provided additional insight into the fact that siRNA mediated knockdown of glycolytic 
enzyme expression inhibits HIF-dependent HRE activity in these cells but not the constitutive 
CMV-luciferase found in a paired cell line which we generated, suggesting that these enzymes 
are indeed critical for cellular HIF activity rather than solely inhibiting general luciferase activity 
in our endpoint assays (Figure 10).   
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Figure 10. Glycolytic Enzyme Expression is Critical for Global HIF Activity 
786-0 renal adenocarcinoma cells were used to demonstrate the effect of glycolytic enzyme knockdown on global HIF 
activity since these cells express no HIF-1α; instead they express only HIF-2α. Additionally, a complimentary 786-0 
line was generated with a constitutively active CMV-luciferase reporter and was used to show that siRNA mediated 
silencing of glycolytic enzymes reduces luciferase activity in a HIF dependent manner rather than global luciferase 
inhibition.  Scrambled non-targeting and HIF-2α siRNAs served as controls. 
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ALDOA knockdown also resulted in the greatest inhibition of cell proliferation amongst the 
panel of selected hits from the global siRNA screen. Following identification of the initial hits 
from the original, pooled library screen, a second siRNA manufacturer was identified (Qiagen) 
and individual oligos for selected targets were ordered and tested. By selecting sequences from 
a second manufacturer, the potential for siRNA off-target effects experienced in the primary 
screen can be overcome by two mechanisms. First, the deconvolution of the original pooled 
library which contained four sequences targeting a single gene in a single well can be screened 
independently. Second, by using a sequence different than that found in the original pool, the 
documented phenomenon of exogenous introduction of siRNA into a cell and subsequent 
possible downregulation of the expression of a large subset of genes in a microRNA-like 
manner [79-81] can be overcome. Since only short regions of sequence homology between the 
siRNA and target sequences are required for this effect, a greater variety in the tested 
sequences adds confidence during validation steps. Results from the primary screen were 
validated in this way using all four cancer cell lines previously mentioned for ALDOA, PGK1 and 
PGK2 with comparable results amongst the lines (Table 3).  
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  Median Relative Luciferase Units (HRE Luciferase/Viability) 
Sequence 
ID 
Accession 
Number Gene ID 
MIA PaCa-2 
HRE 
PANC-1 
HRE 
MDA-MB-231 
HRE 
HT-29 
HRE 
Oligo 1 NM_000034 ALDOA 24.41 33.07 26.70 79.85 
Oligo 2 NM_000034 ALDOA 23.21 23.10 23.16 20.23 
Oligo 3 NM_000034 ALDOA 22.54 22.32 22.94 21.42 
Oligo 1 NM_000291 PGK1 50.78 38.40 25.68 30.59 
Oligo 2 NM_000291 PGK1 43.60 30.83 26.01 44.54 
Oligo 3 NM_000291 PGK1 53.25 49.33 39.59 30.04 
Oligo 1 NM_138733 PGK2 92.98 64.60 49.88 56.49 
Oligo 2 NM_138733 PGK2 17.49 16.81 15.34 18.71 
Oligo 3 NM_138733 PGK2 34.88 21.55 13.55 23.63 
 
 
Table 3. ALDOA Knockdown Shows Greatest Inhibition of HRE Activity in Secondary Validation 
Using siRNA from a second manufacturer, individual oligos from the original pool are deconvoluted and screened 
individually. As a result, Aldolase A was again confirmed to have the greatest effect on HRE luciferase activity 
following siRNA knockdown. 
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Dual transfection of siRNAs targeting PGK1 and PGK2 suggested overlapping activities as 
the combined, double knockdown gave at least additive inhibition of HRE-luc activity, without 
significant inhibition of cell proliferation (Figure 11).  ALDOA and PGK1 or PGK2 knockdown 
inhibited cellular glycolysis, as measured by Seahorse® technology, in all lines (Figure 12) and, 
additionally, markedly decreased cellular ATP in hypoxic MIA PaCa-2 and PANC-1 cells (Figure 
13). HIF-1 knockdown was included as a control and resulted in a similar decrease in ATP level, 
as expected due to decreased overall glycolysis. The results suggested to us that the effects of 
ALDOA and PGK1/2 on HIF-1 could be mediated by AMPK that is commonly activated in 
response to elevated AMP when cell ATP levels are lowered [82, 83].  
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Figure 11. Dual Transfections of siPGK1 and siPGK2 Suggest Redundant Function 
The additive effect on HRE-luciferase inhibition in dual transfected samples suggests inhibition of both PGK1 and 
PGK2 isoforms is needed to achieve significant levels of hindrance of HIF activity; further development of PGK 
inhibitors would require dual action. 
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Figure 12. siRNA Knockdown of Key Glycolytic Enzymes Inhibits Cellular Glycolysis 
The rate of cellular glycolysis and glycolytic reserve (defined as excess glycolytic capacity following Oligomycin-
mediated inhibition of mitochondrial oxidative phosphorylation) was measured using Seahorse® technology, as 
illustrated in the data key at left in all four of the HRE-luciferase lines used throughout various experiments in this 
work (PANC-1 and MIA PaCa-2 pancreatic, MDA-MB-231 metastatic breast and HT-29 colon cancer lines). 
Measurements were taken after reverse transfection with siRNA targeting ALDO isoforms A, B and C (either 
separately or pooled), PGK1 and PGK2 (separately or pooled). Scrambled, non-targeting, and HIF-1α siRNAs served 
as controls. Bars represent standard deviations from four biological replicates for each sample. 
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Figure 13. siRNA Knockdown of Key Glycolytic Enzymes Inhibits Generation of ATP 
Cellular ATP levels 72 hours after transfection with siRNA targeting HIF-1α, ALDOA, and PGK1 or 2 and 16 hours in 
hypoxia. Bars represent standard deviation from three separate experiments. 
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HIF-1α Activity is Mediated by AMPK Activation and EP300 Inactivation 
We first established that, in all cells, decreased HIF-1 activity caused by ALDOA or PGK1 or 
2 knockdown occurred without changes in HIF-1 protein levels and was qualitatively similar in 
normoxia or hypoxia, although an overall greater effect was seen in hypoxia when HIF-1 levels 
are elevated (Figure 14). To evaluate possible mechanisms underlying this activity we co-
transfected glycolysis-related siRNAs with siRNAs targeting proteins that are known to regulate 
HIF-1 activity;  [84, 85]. We found that AMPK siRNA rescued the effects of ALDOA or PGK2 
knockdown on HIF-1 inhibition, but observed little effect when glycolytic siRNAs were 
transfected with p300 or PCAF siRNAs (Figure 15). FIH siRNA also reversed the effects of 
ALDOA and PGK1 on HIF-1 activity, likely due to loss of negative regulation of HIF-1. Evidence 
that the effect is mediated through AMPK regulated actions were further confirmed when the 
effect of ALDOA or PGK1 or PGK2 knockdown was abolished following treatment with the 
AMPK inhibitor dorsomorphin (Figure 16). Furthermore, western blotting showed that ALDOA 
knockdown significantly increased phosphorylation of AMPK on Thr172, a marker of AMPK 
activation in response to cellular stress such as ATP depletion [86-89], in both normoxia and 
hypoxia (Figure 17).  
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Figure 14. Knockdown of ALDOA or PGK1 or 2 Inhibits HIF-1 Activity Without Decreasing HIF-1α Protein 
Levels.  
HIF activity was measured in air (Normoxia) or 1% O2 (Hypoxia) using four cancer cell lines of various types stably 
transfected with the HRE-luciferase reporter 72 hr after transfection with siRNA targeting ALDOA or PGK1 or 2 and 
after 24 hr in hypoxia. Bars represent S.D.  HIF-1α protein was also measured by Western blotting.  Scrambled, non-
targeting, and HIF-1α siRNAs served as controls. 
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Figure 15. Dual Transfections Suggest AMPK Responsible for Glycolytic Regulation of HIF Activity 
Dual reverse transfection of siRNAs targeting ALDOA or PGK1 or 2 plus siAMPK (protein kinase, AMP-activated, 
alpha 2 catalytic subunit), siEP300 (E1A-associated cellular p300 transcriptional co-activator protein), siPCAF 
(p300/CBP-associated factor), and siFIH (Factor Inhibiting HIF-1). Results indicate that AMPK inhibition mediates the 
effects of loss of ALDOA or PGK1 or 2 on HIF-1 activity. 
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Figure 16. Inhibition of AMPK Activity by siRNA Knockdown or Treatment with AMPK Inhibitor Leads to HIF 
Activity Recovery Following Glycolytic Enzyme Knockdown 
 
HIF-1 activity following knockdown of ALDOA, PGK1, or PGK2 72 hr after transfection and after 24 hr in hypoxia 
(filled boxes). Effects are rescued following treatment with the AMPK inhibitor dorsomorphin at 5 µM or with siRNA 
targeting AMPK (open boxes). “*” indicate a p value less than .05 comparing siTarget to dual transfections of siTarget 
and siAMPK; “ǂ” indicate a p value less than .05 comparing siTarget + DMSO treatment with siTarget + 5 micromolar 
dorsomorphin treatment 
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Figure 17. ALDOA Knockdown Results in Hyper Activation of AMPK  
Western blot showing enhanced phosphorylation of AMPK (at Thr172 following silencing of ALDOA, or PGK1 or 
PGK2 72 hours after siRNA transfection and after 24 hours  in hypoxia in MDA-MB-231, HT-29, MIA PaCa-2 and 
PANC-1 cells harboring the HRE-luciferase reporter. 
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We next addressed how activation of AMPK (5'AMP protein kinase) by phosphorylation on 
its activating loop at Thr172 in response to increased AMP, formed from ADP through adenylate 
kinase [90], could lead to inhibition of HIF-1 transcriptional activity. AMPK phosphorylates many 
downstream substrates, one of which is p300/CREB binding protein (p300/CPB) [91] a nuclear 
transcription factor necessary for HIF-1 transcriptional activity [92].  Unlike other phosphorylations 
of p300/CPB, phosphorylation on Ser89 by AMPK specifically blocks its transcriptional activity 
by interfering with its ability to act as a histone acetyltransferase [91].  Phosphorylation of p300 at 
Ser89, which we observed following knockdown of ALDOA or PGK2 particularly in hypoxic 
conditions, occurs following AMPK activation, attenuating the interaction of p300 with numerous 
nuclear receptors in vitro and in vivo [93] (Figure 18).  Thus the mechanism we are proposing for 
the regulation of HIF-1 activity by glycolysis inhibitors is that, in response to lowered ATP, 
AMPK is activated and phosphorylation of p300/CREB at Ser89 leads to its dissociation from 
HIF-1 leading to decreased HIF-1 transcriptional activity. 
 
 
 
 46 
 
Figure 18. EP300 Phosphorylation Mediates AMPK Effects on HIF-1 Activity 
Western blot showing enhanced phosphorylation of AMPK (at Thr172) and p300 (at Ser89) following silencing of 
ALDOA, or PGK1 or PGK2 72 hours after siRNA transfection and after 24 hours in hypoxia in HT-29, MIA PaCa-2 
and PANC-1 cells harboring the HRE-luciferase reporter. 
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To investigate this further, EMSA analysis of MDA-MB-231 HRE luc cells with siRNA 
mediated knockdown of ALDOA show a complete loss of HIF-1 binding to HRE sequences on 
DNA. Dual transfection of both siALDOA and siAMPK result in a restoration of HIF-1 binding 
(Figure 19). These results suggest that inhibition of glycolysis and a concomitant decrease in 
HIF-1α activity are mediated by AMPK activation, possibly in response to low cellular ATP 
levels, which in turn promotes p300 phosphorylation and terminates its ability to co-activate HIF-
1 transcriptional activity (Figure 20).  
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Figure 19. siRNA Mediated Knockdown of ALDOA in MDA-MB-231 Cells Results in Loss of HIF-1 DNA 
Binding Ability.   
Electrophoretic Mobility Shift Assay showing complete loss of HIF-1 binding to HRE sequences following knockdown 
of ALDOA. Binding ability is restored with coincidental knockdown of AMPK. 
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Figure 20. Proposed Mechanism of Glycolytic Control of Cellular HIF-1 Activity 
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Variable Expression of Aldolase Isoforms Suggest Compensatory Effects on Glycolysis  
To further understand variable effects of ALDOA knockdown on proliferation amongst the four 
HRE luciferase lines we next conducted immunoblotting to analyze expression of Aldolase B 
and C isoforms in normoxia and hypoxia to uncover possible compensatory mechanisms when 
ALDOA is eliminated. Interestingly, we found that the HT-29 HRE line, which shows only 
minimal decreases in cell viability after ALDOA knockdown, exhibits significantly higher 
expression of ALDOA compared to MDA-MB-231, MIA PaCa-2 and PANC-1 lines, which show 
significant decreases in viability following ALDOA knockdown (Figure 21). Additionally, high 
expression of ALDOC in the HT-29 line suggests a possible compensatory effect in the absence 
of ALDOA at this step of glycolysis. Irregular expression patterns of ALDOA and PGK1 and 
PGK2 proteins were confirmed by western blot analysis in 12 lung cancer cell lines (Figure 22).  
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Figure 21. Aldolase Expression Level Correlates with Sensitivity to siRNA Mediated Knockdown  
Cells expressing low levels of ALDOA are especially sensitive to siALDOA knockdown while cells expressing high 
levels are less sensitive. 
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Figure 22. Differential Expression of ALDO or PGK Isoforms in Cancer Cell Lines 
The panel of cell lines used in Western blot analysis of PGK1, PGK2 and ALDOA was expanded to include cell lines 
from various tumor types and stage.  Densitometry analysis of western blots of lysates from these lines compares the 
induction measured between normoxia and hypoxia treated samples. 
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Inducible ALDOA knockdown Extends Median Survival in an in vivo Model of Metastatic 
Breast Cancer  
 
To validate ALDOA as a potential therapeutic target and because we have shown that ALDOA 
knockdown is acutely toxic to cancer cells in vitro we expressed a doxycycline-inducible ALDOA 
shRNA in MDA-MB-231 HRE-luciferase cells, and then used those cells to establish an 
orthotopic model of metastatic breast cancer in female NOD-SCID mice. Two clonal lines 
showing complete (clone 8.8) or partial (clone 9.7) ALDOA knockdown and glycolysis inhibition 
following doxycycline treatment were used (Figure 23). Mice fed doxycycline either one week 
before implantation of cells or when the primary tumor reached approximately 250 mm3 showed 
increased median lifespan. Mice fed doxycycline a week before implantation showed increases 
from 37 days in parental, and 41 days in empty vector transfected cells, to 50 and 56 days in 
two clonal cells lines (p<0.001in both cases); mice treated once tumors were established 
showed increases from 41 days (untreated) to 48 days (p < 0.001 compared to control) (Figure 
24). Since the inducible shALDOA vectors were transduced into HRE-luciferase cells, 
transdermal fluorescence imaging of the mice was made possible as a measure of HIF activity 
in vivo. With this additional measure, we hypothesize that the extended life expectancy as a 
result of shALDOA knockdown can be partly attributed to an inhibition of HIF activity since 
luciferase readings in mice with sh8.8 showed significantly lower mean luciferase readings in 
both pre-treated and doxycycline treated established tumors compared to tumors established 
from the parental cell line (Figure 25). Postmortem analysis of mice indicated significant 
metastasis from the primary tumor to the lungs and liver in tumors derived from parental lines 
but not from tumors derived from the transduced clones.   
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Figure 23. Inducible shALDOA MDA-MB-231 Breast Cancer Lines Established for Use in in vivo Studies.   
Two lentiviral shALDOA doxycycline-inducible clones of MDA-MB-231 metastatic breast cancer cells were 
established (clones 8.8 and 9.7). Both show doxycycline-inducible ALDOA knockdown together with inhibition of 
glycolysis (as assessed using Seahorse® technology) and reduced HIF-1α activity, based on activity of the HRE-
luciferase reporter measured under hypoxic conditions. 
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Figure 24. Inducible ALDOA Knockdown in MDA-MB-231 Breast Cancer Tumors Extends Survival of 
Xenografted Mice.   
Groups of 5 immunodeficient SCID mice were injected in the breast fat pad with 1x106 MDA-MB-231 parental or 
vector-only cells, or with clones 8.8 or 9.7. Animals received dietary doxycycline (625 mg/kg) starting 7 days before 
injection of cells or when tumors reached approximately 250 mm3. Death occurred in all cases associated with 
metastasis of the MDA-MB-231 cells to the liver and lungs. Median survival of mice with parental MDA-MB-231 
tumors was 37 days and with empty vector cells 41 days. Following doxycycline treatment mice injected with clone 
8.8 or clone 9.7 cells 7 days before cell injection had a median survival of 56 days and 50 days, respectively (p<0.001 
relative to combined controls groups in both cases). Animals receiving doxycycline treatment when the tumors 
reached ~ 250 mm3 had a median survival of 41 and 48 days (p<0.001 compared to combined control groups in both 
cases). At the time of death, lungs and liver of the mice showed extensive metastatic nodules. 
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Figure 25. Inducible ALDOA Knockdown in MDA-MB-231 Breast Cancer Tumors Reduces HIF Activity in vivo 
In vivo HIF-1α activity was determined using the MDA-MB-231 HRE-luc highly metastatic breast cancer cell line after 
induced silencing of Aldolase A with shRNA. Mice (n=5/group) were measured with Xenogen IVIS imaging system 
and intraperitoneal injection of luciferin starting 14 days after cell implantation. Silencing of Aldolase A resulted in 
significant inhibition of HIF-1α activity either in subjects that received doxycycline before cell implantation (doxy pre 
injection group) or after tumors had grown to 250 cubic millimeters (doxy @ 250 mm3 group). * P<0.01 for both 
groups relative to non-transduced MDA-MB-231 HRE-luc cells receiving equal doxycycline treatment. 
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Carrying murine xenograft data forward and in order to determine the clinical relevance and 
therapeutic implication of novel Aldolase inhibitors for patients with a variety of tumor types, we 
examined whether expression levels of various Aldolase isoforms correlated with any 
measureable differences in overall patient survival. Aldolase A, B and C mRNA expression data 
was obtained from the PANCAN dataset from The Cancer Genome Atlas (TCGA) (n = 9755). 
Using the TCGA expression data, we found that elevated Aldolase A and C expression was 
significantly correlated with poor prognosis in regards to survival rates (p < 0.0001 in both 
cases) even when corrected for cancer type and patient age and sex (Figure 26). Alternatively, 
no difference in PFS is observed between high and low level expression of Aldolase B (Figure 
27), suggesting that A and C isoforms are more significantly associated with progression to 
advanced disease states. Collectively, this data indicates that Aldolase isozymes are both 
attractive targets for therapeutic intervention in cancer progression and could also serve as 
critical diagnostic factors for determining patient response to therapy and overall prognosis. 
ALDOA expression is clearly associated with poor clinical prognosis of a variety of cancer types, 
suggesting that its expression patterns could be used in advance to select patients in which 
Aldolase inhibition would be both beneficial and critical for overall patient health. 
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Figure 26. The Cancer Genome Atlas Data Suggests Aldolase A and C Isoform Expression Data Predicts 
Overall Patient Survival 
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOA and ALDOC mRNA suggests 
high expression of either in patient tumors could be predictor of poor prognosis. Survival data is corrected for tumor 
type, patient age and patient sex. 
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Figure 27. The Cancer Genome Atlas Data Suggests Aldolase B Isoform Expression Data Cannot be Used as 
a Predictor of Overall Patient Survival 
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOB mRNA suggests high 
expression of the protein in patient tumors has little to no predictive value. Survival data is corrected for tumor type, 
patient age and patient sex. 
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Considering the differential expression of ALDOA in cell lines and the correlative 
pattern that we observed in regards to sensitivity to its knockdown, we next analyzed 
available TCGA expression data and found, upon initial analysis, that elevated Aldolase 
A expression was significantly correlated with lower median survival in a variety of 
cancer types pointing to its potential value as a prognostic factor in the treatment of 
such diseases with novel inhibitors currently under development (Figure 28). 
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Figure 28. Variable Expression of ALDOA in Tumors Predicts Median Survival 
Initial consideration of TCGA data following cell line analyses shows a pattern of poor prognosis with high ALDOA 
expression relative to paired normal tissue. 
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Discussion: 
HIF-1α is a key transcription factor that functions in cell survival in stressful hypoxic 
environments established by many solid tumors due to poor vascularization.  Amongst these 
targets are pro-angiogenic genes such as PDGF and VEGF [23, 26, 28, 94], genes associated with 
accelerated tumor cell proliferation such as MYC [95, 96], and genes functioning in migration, 
invasion and remodeling of the extracellular matrix and contributing to increased cell survival 
and heightened metastatic potential [97-99]. HIF-1 promotes cell survival by up-regulating genes 
related to cancer cell metabolism and rapid production of ATP and glycolytic metabolites [4, 29, 
100].  Increased HIF-1α signaling is observed in many pathophysiological conditions, including 
pancreatic, colon and breast cancers. However, inhibitors designed to disrupt HIF-1’s protective 
role have thus far been largely ineffective. Thus we took an unbiased approach by utilizing a 
high-throughput siRNA screen to identify factors that mediate HIF-1α transcriptional activity, in 
part to reveal novel targets for HIF-1α inhibition. Unexpectedly, several hits in the screen were 
enzymes functioning in glycolysis.  While it was previously known that HIF-1 increases the 
glycolytic rate in tumors by inducing expression of glycolytic enzymes [4, 5, 27, 29, 100], it has not 
previously been reported that glycolysis increases HIF-1 activity.  We found that 16 of 30 
glycolytic enzymes and isoforms were associated with some inhibition of HIF-1 transcriptional 
activity. Among them, ALDOA and PGK 1/2 knockdown resulted in robust inhibition of HIF-1 
activity in all lines tested. 
Cellular protein synthesis is energetically expensive; thus protein synthesis rates are tightly 
regulated in order to couple nutrient availability to signals driving proliferation.  It is known that in 
an energy crisis when glycolysis is inhibited, ATP levels decrease and AMPK is activated 
subsequently leading to mTOR mediated decreased expression of HIF-1 protein [101]. However, 
under hypoxic conditions, as found in solid tumors, decreased degradation of HIF-1, at least in 
the short term, increases levels of HIF-1 protein, which paradoxically obscure potential 
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decreases in translation. However, we now report that HIF-1 protein is not transcriptionally 
active when glycolysis is inhibited. The EP300 co-activator is required for numerous signaling 
pathways governing cellular proliferation and differentiation, processes tightly controlled by p300 
phosphorylation status [102]. Specifically, p300 phosphorylation at serine 89 following AMPK 
activation dramatically reduces p300 interaction in vitro and in vivo with numerous nuclear 
receptors but does not alter interaction with non-nuclear receptors [93]. We confirmed these 
findings in glycolysis inhibition following knockdown of ALDOA, or PGK1 and PGK2, suggesting 
that control of the transcriptional machinery by activated AMPK is achieved through disruption of 
normal cancer cell metabolism. Thus, in response to lowered cellular ATP levels, AMPK is 
activated and p300 phosphorylation at Ser89 promotes dissociation from HIF-1α, decreasing its 
transcriptional activity.  
Interestingly, HIF-2α activity is also subject to inhibition when glycolysis is inhibited as we 
observed in the case of the 786-O renal line. HIF-1 and HIF-2 upregulate both common and 
unique downstream targets, and HIF-2 does not upregulate glycolysis genes as does HIF-1. 
Thus, we conclude that HIF-2 does not participate in the feed forward loop described here, but 
rather its activity is dependent on HIF-1 stimulation of glycolysis.  Most cancer cells express 
HIF-1 under acute hypoxic conditions, but in prolonged hypoxia HIF-2 is expressed and HIF-1 
levels fall [46]. The consequences of HIF-2 inhibition need to be investigated, particularly in clear 
cell renal cancer cells, which predominantly express HIF-2. 
Here we show that ALDOA and PGK1/2 isoforms are the most critical of 40 isoenzymes of the 
glycolytic pathway in terms of maintenance of normal HIF-1α activity, making both attractive 
targets to inhibit both cancer cell energy metabolism and survival of stress. The marked 
extension in median survival time of mice with ALDOA knockdown in the MDA-MB-231 model of 
metastatic breast cancer confirms this point and opens the possibility of novel drug screening 
and therapeutic options for cancer subtypes linked to HIF-1α and ALDOA expression. 
Furthermore, identification of ALDOA as a potential novel regulator of HIF-1 could be clinically 
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relevant, since ALDOA expression levels are reportedly significantly elevated relative to other 
glycolytic enzymes in several human tumor types [57, 103], providing a novel means to inhibit HIF-
1α function in several solid tumors. Variable expression of Aldolase isoforms in the panel of 4 
HRE luciferase lines used here suggests a compensatory mechanism for ALDOC in the 
absence of ALDOA. In particular, high ALDOC levels seen in HT-29 HRE cells could explain 
why ALDOA knockdown had minimal impact on this line and demonstrate a need for therapeutic 
agents targeting both ALDOA and ALDOC. Variability in the pattern of Aldolase isoform 
expression was further confirmed in a panel of 12 lung cancer cell lines (Figure 23). Currently, 
there are no clinically available inhibitors of these critical steps in glycolysis; establishment of 
agents targeting crucial components of the pathway could be useful to treat cancers that survive 
using these mechanisms.  
Malignant transformation reportedly shifts cells to a pattern of glycolytic enzyme expression 
that favors uncontrolled proliferation and facilitates energy production and metabolite production 
in an oxygen free setting [104, 105] A feed forward loop in tumors promoting increased HIF-1 
activity and increased glycolysis provides a target to block tumor energy production pathways 
and the HIF-1α survival response. Our activity-oriented RNAi screen and subsequent 
mechanism-based analysis expands our understanding of known and novel regulators of the 
HIF-1α transcription factor and suggest previously uncharacterized regulation of HIF-1 activity 
by glycolytic enzyme expression. Moving forward, by designing a therapeutic intervention for 
ALDOA activity, we hope to inhibit both cancer cell metabolism and the tumor cell’s ability to 
survive hypoxic stress thus exploiting a dual Achilles’ heel of the cancer cell. 
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Chapter 2: Designing a Chemical Probe 
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Virtual High Throughput Screening Quickly Characterizes Potential Lead Compounds 
In the realm of rational drug design, molecular docking programs are frequently used to 
predict the binding orientation of small molecule pharmacological probe candidates to targets of 
interest in the form of proteins or, more specifically, enzymes in order to predict the affinity that 
the small molecule has for the active site of that target [106]. In this way, the use of recursive 
docking programs in screening operations can play a critically important role in the rational 
design of new pharmaceutical agents. Given the biological and pharmaceutical potential of 
these molecular docking systems, considerable efforts have been directed towards the design 
of new methods and tools that can be used to predict docking [106]. 
Taking into account the availability of small molecule data bases, these screening 
methodologies can be focused on drug-like molecules that are either commercially available for 
testing in biological assays or can be easily generated from already available materials or 
processes. In this way, the characterization of available chemical compounds, natural products 
and drugs can be accomplished in such a way as to gain an understanding as to what basic 
structures stand to give the greatest effect against the target of choice and manipulated later for 
SAR based studies [107]. 
GOLD (Genetic Optimization for Ligand Docking) is a program for calculating the likelihood 
of certain docking conformations of small molecules in specifically outlined protein binding sites 
as determined by the program’s user [108]. The automated ligand docking program uses a 
genetic algorithm to explore the full range of possible ligand conformations within a specified 
binding site with partial flexibility of the protein at that site, and satisfies the requirement that the 
ligand of interest displaces loosely bound water on binding. The software package consists of 
several programs; the first, for visualization and manipulation of the unadulterated protein 
structure as input from the protein databank, a second for the calculation based protein-ligand 
docking screening algorithm and a third for post-processing and visualization of the docking 
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results from high-throughput virtual screening.  An extensive review of literature outlining 
information regarding both the crystal structure of the Aldolase A isozyme and studies of the 
effect of mutation of specific residues on the functionality of the enzyme yielded a set of six 
critical residues to be included in the specifically outlined protein flexibility algorithm: Asp33, 
Ser38, Lys146, Arg148, Glu187, and Lys229.   The program, by including protein side chain and 
backbone flexibility in this user defined list of residues within the protein of interest, takes into 
account the wide range of possible conformations of not only individual substrates but also the 
enzyme itself during the virtual docking mechanisms.  The results of the survey of the literature 
were visualized and manipulated in PyMOL, a molecular visualization system capable of 
translating Protein Data Bank files into high quality 3D images [109] (Figure 29).  
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Figure 29: Computer model of active binding site of Aldolase A isozyme 
Using the published available crystal structure for Aldolase A (4ALD in PDB), PyMOL was used to visualize the 
surface of the active binding site of the enzyme (orange) to contrast the cartoon version of the enzyme as a whole 
(teal) and Fructose-1,6-bis(phosphate), the enzyme’s natural substrate (shown in dark blue). Using this method, key 
residues in the binding site were identified for virtual screening methodologies. 
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Virtual High Throughput Sigma TimTec Myria Screen Uncovers Novel Tool Compounds 
For the purposes of this study, GoldScore, the original scoring function within a range of 
possible criteria sets for assessment of ligand binding, was selected as it has been optimized for 
the prediction of ligand binding positions and takes into account factors such as H-bonding 
energy, van der Waals forces and strain on the ligand itself given specific conformational 
changes [110]. Additional features that made this scoring function ideally suited for this particular 
project were alluded to earlier, as GoldScore is the only scoring function that takes into account 
flexible residues within the targeted binding site - in cases where program users are docking a 
ligand into a binding site known to contain a flexible side chain (such as the Aldolase isozymes), 
it is possible to specify that these residues be allowed to undergo automatic rotation around one 
or more of its acyclic bonds. Since it was determined from literature review that there were at 
least six critical residues that were capable of torsional rotation, this was the clear choice for 
appropriate scoring functions [111-113]. In this way, the conformations of the flexible motifs were 
altered during docking in order to optimize the hydrogen bonding interactions of the residue with 
the ligand, improving the final indication of likelihood of binding affinity. 
Using the solved crystal structure (4ALD from Protein Data Bank) and the parameters as 
outlined above, the Sigma TimTec Myria library of 10,000 compounds was selected for initial 
screening.  The value of this library was the careful consideration of several physical and 
chemical properties by the library’s designers at both Sigma and TimTec including the diversity 
of molecular weight, cLogP (measure of relative hydrophobicity), hydrogen bond acceptors, 
hydrogen bond donors, and rotatable bonds. Further, the collection is largely drug like according 
to Lipinski’s Rule of 5 [114] which was useful for this screening operation in that we were 
interested in identifying novel inhibitors that could be made into pharmacological probes for 
further drug design efforts.  Each of the 10,000 compounds was docked in five possible 
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conformations in order to yield a range of scores for each compound taking into account several 
possible docking scenarios within the active site. 
If the system were perfect, the calculated binding energy of a specific substrate would 
correlate perfectly with an experimental binding energy, so that the pose with the lowest 
predicted binding free energy would correspond directly to the experimentally determined 
structure. Since the process of free energy calculation is confounded by many factors 
surrounding the interaction between the substrate and specific residues within the binding site, 
this is not always the case; for this reason, it is often found that the lowest energy structure 
predicted by docking will not be the closest to the experimentally determined crystal structure of 
the protein. Molecular docking processes are generally used to simply identify a set of 
compounds to be used in further development experiments rather than to select a single 
compound on which to base all future research. Taking this into account, it was important to 
include a system of checks and balances in the original experimental design in order to 
measure the effectiveness of residue selection.  As a validation of the effectiveness of the 
screening procedure, fructose 1,6-bisphosphate was included with the Myria compound library 
to be included in the list of possible compounds; this natural substrate ranked among the top ten 
compounds according to its binding affinity relative to the compounds found in the screened 
library initially verifying the validity of residue selection for use during the screen. 
Upon completion of the screening operation that considered over 50,000 possible 
permutations of potential small molecule inhibitors and their binding to the active site of ALDOA, 
GOLD fitness was used as a parameter to describe the interaction between the ligand and the 
binding site.  In order to further refine the selection process, several parameters were 
considered: 
 
1. The number of times that each of the five iterations of each compound’s 
conformational changes appear amongst the top ranked hits was taken into account.  
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Logically, a compound that appeared four times in top 20 compounds was more 
likely a worthwhile hit than one that only appears once in the top 100. 
2. Compounds were removed from the list if the cLogP was over 2 since this would 
neither be easy to test in cell models, nor a useful therapeutic agent if in vitro work 
proved the agent was effective at silencing the action of Aldolase A. 
3. For the most part, chemicals that were symmetrical were taken out of the ranks; 
however, there was one compound in the top ten that consistently ranked highly 
according to its GOLD score that was not removed. 
4. The diversity of chemical structures was also considered in the selection process 
since the likelihood that even after early in vitro work each of the chosen structures 
would have to be modified for purposes of SAR studies at a later time was 
considerable. 
 
After cropping the list of top hits from 50,000 to just 100, the top hits were then rescreened 
in GOLD with 20 iterations of possible conformations using a fully flexible binding site model.  
As expected, this process did not have a significant effect on the ranking of each compound. 
Finally, these top 100 compounds were visually inspected in PyMOL relative to the natural 
substrate to make sure that there were not significant changes in the structure of the docked 
complex relative to the proven crystal structure.  This also was effective in showing how each of 
the potential probes fit into the binding site relative to critical residues and the natural substrate 
itself.  During this procedure the list of 100 compounds was again reduced to the top 22 which 
were chosen for in vitro experiments. Since Aldolase is found at a critical point in glycolysis in 
which NADH is oxidized, a simple spectrophotometric assay was employed for this function.  
Optimization experiments to determine the ideal concentration of Aldolase protein for use per 
well in a 96 well plate format gave proof that the assay was robust enough for testing of 
inhibitors from the virtual screen (Figure 30).  
 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Optimization of NADH Oxidation Mediated Aldolase Activity Assay  
Initial work in the development of a multi-well plate assay to measure the activity of ALDOA  has used  a 96 well plate 
assay based on conversion of fructose 1,6-bisphosphate (F-1,6-BP) into glyceraldehyde 3-phosphate (GAP) and 
dihydroxyacetone phosphate (DHAP) measured in a coupled reaction with GAP dehydrogenase by the oxidation of 
NADH to NAD at 364 nm..  This reaction can be easily manipulated by altering initial ALDOA protein concentration in 
the reaction well to produce changes in the velocity of the reaction which are proportional to the amount of active 
ALDOA added. 
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Of the tested compounds, 3-hydroxy-5-(4-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)-4-(2-
thienylcarbonyl)-1,5-dihydro-2H-pyrrol-2-one (referred to as “Compound 6” due to its rank as the 
6th best hit from the GOLD screen) gave the best results in the biochemical assay; however, the 
non- Michaelis-Menten nature of the kinetic profile made the calculation of critical values used in 
the description of an agents effect on enzymatic activity impossible. In order to understand 
these effects on enzyme function, a kinetic description of their activity as measured as the rate 
of catalysis of the natural substrate (described as the rate of product formation) is needed and, 
typically, will vary proportionally with the concentration of the substrate – similar to the profile 
seen in Figure 4. In this case, however, a lag phase in which inhibitory effects of the compound 
are basically absent is observed prior to an immediate drop off (Figure 31). 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31.  Non-Michaelis-Menten Enzyme Kinetics Observed Using ‘Compound 6’  
They typical hyperbolic plot that is found in Michaelis-Menten kinetics is missing with the use of Compound 6 in 
recombinant protein based biochemical assessment of the proposed Aldolase A inhibitor. The 5 minute lag phase 
followed by abrupt loss of Aldolase activity defies traditional enzymatic activity patterns and raises questions 
regarding its activity as an Aldolase inhibitor.  
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High Throughput Small Molecule Screen in vitro Uncovers Novel Pharmacological 
Probes 
Previous work suggests a modification of residues on the C-terminal tail of Aldolase which is 
known to overlay the catalytic site might be responsible for inhibition of activity of the enzyme 
[115]. Since residues in the portion of the target were not considered in the initial GOLD screen, it 
is possible that the results, while initially interesting, did not provide the robust effects that were 
expected and inclusion of these residues in future screening efforts would be needed.  
Considering the effectiveness of the biochemical assay used for the initial assessment of 
hits from the virtual screen, large scale, high-throughput screening of small molecule libraries 
using the assay was a logical next step. Typical assessment of Aldolase activity in vitro was 
achieved through the use of a coupled enzymatic reaction with α-Glycerophosphate 
Dehydrogenase (GAPDH). Since this step of glycolysis causes the conversion of NADH to NAD 
in the presence of the natural products of Aldolase, the absorbance based quantification of 
remaining NADH in solution could indirectly measure Aldolase activity [70].  However, since the 
sensitivity of NADH absorbance is low, and since interference of small molecules with 
absorbance less than the 400 nm wavelength required for the assay could result in high rates of 
false positive identification, an alternative, first of kind, fluorescent based assay was developed 
by medicinal chemists at the University of Texas at Austin (Ashwini Devkota, Eun Jeong Cho 
and Kevin Dalby) in order to swiftly identify lead compounds for therapeutic development of 
Aldolase A inhibitors (Figure 4, 5). The Elite NADH assay, which is marketed as a method to 
measure the levels of NADH/NAD+ in various sample types, was repurposed for use in a highly 
sensitive, high throughput function. The kit’s enzyme reduces a chromophore into a highly 
fluorescent product in states of NADH dehydrogenation. Glyceraldehyde-3-phosphate 
dehydrogenase converts glyceraldehyde-3-phosphate (G-3-P) to 1,3-bisphosphoglycerate (1,3-
BGP) through oxidative phosphorylation. NAD+ is oxidized to NADH when a phosphate group is 
exchanged for a hydrogen on the carbonyl carbon of G-3-P thus converting G-3-P to 1,3-BGP. 
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This assay uses glycerophosphate dehydrogenase to catalyze the conversion of 
dihydroxyacetone phosphate (the product of the ALDOA catalyzed reaction) to glyceraldehyde-3 
phosphate in an NADH-dependent manner.  Thus, the rate of change of fluorescence intensity 
is used to indirectly calculate the activity of ALDOA. After identifying and manipulating this 
system to fit our needs, robustness and reproducibility of the assay was validated through the 
use of Z’-factor calculation in the comparison of positive control (all assay components in the 
absence of ALDOA corresponding to complete enzymatic activity inhibition and, therefore, 
highest fluorescence intensity) and negative control (all assay components in the presence of 
excess ALDOA corresponding to full enzymatic activity of Aldolase and, therefore, lowest 
fluorescence intensity) wells in the presence of an optimized concentration of Aldolase A 
recombinant protein (Figure 32) and Fructose-1,6-bisphosphate substrate (Figure 33) per well. 
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Figure 32.  Assay Optimization: Enzyme Dose Response Versus Time 
Preliminary optimization experiments included the identification of appropriate Aldolase A concentration per well – 0, 
5, 10, and 20 nM recombinant protein were evaluated against standard concentrations of substrate and reaction 
mixture (including glyceraldehyde dehydrogenase). With a reaction completion time of ~30 minutes, 5 nM Aldolase 
was chosen for use in further optimization experiments. 
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Figure 33.  Assay Optimization: Substrate Concentration 
Following the optimization of Aldolase A concentration per well, F(1,6)BP concentration was optimized against 5 nM 
protein and standard NADH and GDH per well. Falling in the linear range of the kinetic profile generated during this 
optimization, 100 µm F(1,6)BP was chosen for the finalized assay parameters. 
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Using this assay, characterization of over 65,000 chemical agents obtained from both 
commercial and academic suppliers was made possible while limiting the likelihood of false 
positives due to interference caused by absorbance inherent to the small molecules alone. 
Similar to the Myria screen used for virtual screening methods described earlier, collections of 
these agents which were selected for functional screening were compiled based on structural 
diversity amongst available biologically active known drugs or natural products and hits were 
selected based on the criteria of 25% inhibition of Aldolase activity following the execution of the 
assay.   
 
Discussion 
By using an unbiased, large scale, small molecule library screen in a recombinant protein 
assay, the typical challenges associated with cell based small molecule screens can be 
overcome.  While many of the compounds found in these libraries have either undetermined 
targets or have been previously identified as inhibitors of proteins other than those that we are 
trying to exploit in this study, early results suggest a promising panel of pharmacological probes 
for the inhibition of normal Aldolase function.  Despite this fact, there are a wide range of cellular 
functions, components of the extracellular space and physiological confounders that can hinder 
the clear efficacy that we observed in the initial screen and further work both in vitro and in vivo 
is required.  
By carrying ‘hit’ compounds into cell based assays a number of parameters could be 
satisfied in an ongoing attempt to design an effective therapy for the ubiquitous processes 
associated with tumor cell metabolism and stress survival.  First, identification of compounds 
which are effective in both biochemical and cell based in vitro experiments can provide novel 
insight about differences between cell types and, in the case of normoxic versus hypoxic cells, 
the inherent variability between different cellular states.  Second, after identifying molecules that 
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are most effective in the cell based assays, new compounds can be designed and generated for 
use in SAR studies in order to optimize analogues with molecular structures that, although 
similar, may have a greater efficacy in target inhibition.  And third, the eventual FDA approval of 
any compound will be almost impossible without a clear understanding of its cellular target and 
the effect that it has in order to achieve its inhibition even if the effect on cancer cell death, HIF 
activity, and energetics is profound. 
While initial findings from our large scale small molecule screen were promising, the 
understanding that physiological components can act as hindrances to a compound’s efficacy 
highlight the need to optimize the pharmacokinetic and pharmacodynamic parameters of our 
early lead compounds.  Delivery of an active compound to the target after escape from 
vasculature, penetration into tumor cells which are distal to the convoluted vasculature of a 
tumor and maintenance of its biologically active form after traveling throughout the body are all 
considerations to be made and overcome in the steps following initial identification of a 
promising hit compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Developing a Novel ALDOA Inhibitor 
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Identification of Lead Compound for Testing Based on Time Dependent Inhibition of 
ALDOA in Biochemical Assay 
In order to confirm that ALDOA is a target with potential for cancer therapy we sought to test 
small molecule probes initially identified as inhibitors of recombinant human ALDOA first in the 
chemical library screen in cell based, biological assays.  Identified in the biochemical assay, 
amongst other compounds, was TDZD-8, a previously described, selective, non-ATP 
competitive GSK-3β inhibitor [116]. In this initial screening assay, this compound showed a time 
dependent inhibition of protein function suggesting a direct interaction with the ALDO protein 
used in the assay (Figure 34). Pointing again to the value and flexibility of small molecule library 
screening, we felt that the identification of a compound with previously described use in cancer 
as an inhibitor of a target other than ALDOA could have value later on in the drug development 
process if proof of this protein interaction could be realized. To that end, a combination of in 
vitro and in vivo experiments investigating this interaction and the effect that it had on cancer 
cells and subsequent xenograft tumors was initiated. 
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Figure 34.  Time Dependent Inhibition of ALDOA Function Suggests Direct Protein Binding 
The small molecule TDZD-8 was discovered as an inhibitor of recombinant human ALDOA activity through a 
chemical library high throughput screen.  Varying concentrations of TDZD-8 were either pre-incubated for 30 minutes 
with recombinant ALDOA or introduced into assay wells at the initiation of the enzymatic assay. In this way, inhibition 
of ALDOA was shown to be time dependent suggesting that TDZD-8 could be interacting directly with the protein. 
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X-ray Crystallography Implies Cysteine Residues Distal to Active Site are Critical for 
Normal ALDO Function 
 
To address the matter of TDZD-8 interaction with the ALDOA protein, X-ray crystallography 
studies were initiated in which ALDOA crystals were soaked with the inhibitor to measure 
residues which might be responsible for the inhibitory effects that we observed in the primary 
screen. Human ALDOA is found as a tetramer [68, 117], and our X-ray crystallographic studies 
showed that TDZD-8 bound with full occupancy to Cys289 in each of the four ALDOA subunits 
of the tetramer, and with partial occupancy at Cys239.  Both Cys residues are on the surface of 
the tetramer and distal to the catalytic site (Figure 35), so their mechanism of inhibition is 
currently unclear.  Interestingly, the literature survey that lead up to virtual high throughput 
screening methodologies used at the start of this drug discovery effort did not include residues 
outside of the substrate binding site; that said, the results from this study came as a surprise. 
The reaction of 1,2,4-thiadiazoles with the Cys sulfur leads to opening of the thiadiazole ring 
between the nitrogen and sulfur and formation of an irreversible disulfide bond. This is a 
relatively slow reaction that is dependent on the nucleophilicity of the cysteine sulfur [118], which 
may account for the slow reaction in the ALDOA inhibition studies that we observed previously 
(Figure 34). The S-S bond may also be stabilized by a hydrogen bond between the carbonyl 
oxygen at the 3-position in the ring, designated as the “recognition arm” [119] and an H-bond 
donor in the protein.  The electron density is fully consistent with disulfide bond formation and 
ring-opening. It is significant that there was marked loss of inhibition by TDZD-8 when ALDOA 
Cys289 was mutated to Ala further implicating this residue in inhibitory effect of the agent on 
ALDOA functionality.  
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Figure 35.  Cys239 and Cys289 Binding Appear Critical for Inhibition of ALDOA Function 
Human recombinant ALDOA crystals were soaked with TDZD-8 and refined at 2.5 Å resolution to an R-factor of 20% 
(RFREE = 24%). The crystal structure showing TDZD-8 (blue and red stick structure) bound specifically to Cys-289 of 
each monomer in the tetrameric ALDOA complex; and to a much lesser extent to Cys-239.  The electron density 
supports the formation of an S-S bond between protein and inhibitor and concomitant breaking of the S-N bond within 
the 1,2,4-thiadiazole ring. In general, density for the terminal Phe group is weak or non-existent, consistent with its 
flexibility. There is no evidence for modification of any other Cys residues. Both modified Cys residues are located 
distal to the catalytic pocket of ALDOA, (shown by a black and red stick structure of a partial substrate analog) and 
their mechanism of ALDOA inhibition is currently unclear.  It is noteworthy that TDZD-8 bound better to ALDOA 
crystals when they were co-crystallized (i.e., prebound) with the substrate analog. 
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Assessment of Glycolytic Substrates, Intermediates, and Products Suggests Aldolase 
Inhibition 
 
The YSI 7100 Multiparameter Bioanalytical System Analyzer allows for focused analysis of 
specific metabolites in biological samples. To measure a substrate of interest, one or more 
enzymes are immobilized between two membrane layers in the instrument’s sensor. YSI 
membranes contain three layers. The first layer limits the diffusion of the specific substrate into 
the enzyme layer and prevents the reaction from becoming enzyme-limited. The third layer 
excludes nearly all electrochemical compounds from interfering with the measurement of 
hydrogen peroxide as the endpoint product. Using this robust system, the swift quantification of 
various substrates, intermediates, and products of the glycolytic process can be carried out.  In 
addition to the XTT and luciferase assays used to show its inhibition of cancer cell proliferation 
and HIF-1 activity (Figure 36) and the reduction in ECAR observed when using the Seahorse 
BioScience® XF96e platform that is consistent with glycolysis inhibition, we were also able to 
show that TDZD-8 inhibited glycolytic activity at low µM concentrations by quantifying the ratio 
of lactate and glucose using the YSI platform (Figure 37). Lastly, GC-MS technology was 
employed for metabolic flux analysis using stable isotope labeling in which the absolute 
quantities of critical intermediates were assessed.  Most notably affected were 
dihydroxyacetone phosphate (DHAP) and pyruvate suggesting that Aldolase was being inhibited 
following treatment with TDZD-8 (Figure 38). Despite not seeing overall inhibition of glycolysis 
(i.e. relatively constant levels of 3PG, PEP and lactate) we suspect that the inhibitor is still 
having an overall negative effect on the cell’s ability to conduct glycolysis and that this is only a 
reflection of intracellular pool sizes of specific glycolytic intermediates, especially considering 
the significant reduction in DHAP concentration per sample following treatment. 
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Figure 36.  TDZD-8 Inhibits Cancer Cell Proliferation and HIF-1 Activity in vitro 
Panel showing in vitro TDZD-8 inhibition at low micromolar IC50 concentrations of cellular HIF-1 activity (as 
measured with the HRE luciferase reporter) and cancer cell proliferation. 
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Figure 37.  TDZD-8 Inhibits Glycolytic Activity in vitro 
Panel showing in vitro TDZD-8 inhibition at low micromolar IC50 concentrations of cellular glycolytic activity as a 
function of both the Extra Cellular Acidification Rate (ECAR) as measured by Seahorse® Technology and the ratio of 
lactate to glucose in the medium as measured by YSI technology. 
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Figure 38.  GC/MS Analysis Shows TDZD-8 Inhibition of Glycolysis in vitro 
GC-MS analysis of cell lysates after 6 hours of treatment with TDZD-8 (20 µM) of MDA-MB-231 cells shows a 
reduction of DHAP, the direct product of Aldolase, and pyruvate suggesting an inhibition of cellular glycolysis.  Amino 
acids whose levels are not known to be affected by glycolysis were included as assay controls. 
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TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo 
Although TDZD-8 is a reactive molecule, our results support a significant level of specificity 
and we used it as a pharmacological probe to see if we could inhibit ALDOA in vivo and solicit 
an antitumor effect.  When administered intraperitoneally daily for 20 days at a dose of 12 
mg/kg/day to mice with MDA-MB-231 orthotopic breast cancer tumors, TDZD-8 caused 
significant slowing of tumor growth by about 60% by day 32. Pharmacokinetic studies showed 
no detectable parent compound in the mouse plasma, but pharmacodynamic studies after a 
single dose of TDZD-8 showed about a 50% decrease in tumor lactate levels within 4 h, a 40% 
decrease in dihydroxyacetone phosphate (a product of the cleavage of fructose-1,6-
bisphosphate by ALDOA), and a slower decrease over a period of days in downstream 
phosphoenolpyruvate (Figure 38). Thus, TDZD-8 itself at low levels or an active metabolite 
appears to reach the tumor to inhibit tumor glycolysis and is associated with measureable 
antitumor activity.  
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Figure 39.  TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo 
TDZD-8 at daily doses of 12 mg/kg by intraperitoneal injection daily for 20 days to immunodeficient SCID mice with 
MDA-MB-231 tumor xenografts shows significant inhibition of tumor growth.  There were 10 mice per group and bars 
are S.E. of the mean. * p = < 0.05 and  ** p = <0.01 compared to control mice. MDA-MB-231 xenografts (~ 250 mm3) 
were also collected at 1 and 4 hr after a single intraperitoneal dose of TDZD-8 of 12 mg/kg, or 4 hr after the last of 5 
daily doses (Q5D + 4),  and tumor levels of lactic acid, dihydroxyacetone phosphate (DHAP) and 3 phosphoglycerate 
were measured. Values are the mean of 4 mice each and bars are S.E.  * p = < 0.05 compared to non-treated control 
tumors. 
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Discussion 
We initially identified a link between glycolytic gene expression and HIF-1 as a promising 
target with potential for development of selective inhibitors of both cancer energetics and stress 
survival. Of the key enzymes found in the glycolytic pathway that came out as interesting genes 
in the primary screen, ALDOA was selected as a gene that had a high level of selectivity for the 
inhibition of global HIF activity in the cell and a drug discovery effort was initiated in order to 
identify novel pharmacological probes of the enzyme.  Combining both virtual and biochemical 
based high throughput screening methodologies, a putative small molecule inhibitor was 
identified and found to be effective in the inhibition of glycolysis, HIF activity and cell viability.  
Measurement of extracellular flux and the corresponding ECAR by Seahorse ® technology 
was used as a proxy for lactate production was a key first glimpse into TDZD-8’s activity as a 
potent inhibitor of both the basal and maximal glycolytic rates in cancer cells. Taking the 
analysis of glycolysis inhibition a step further, GC/MS was employed to investigate the effect 
that TDZD-8 treatment had on pool sizes of key glycolytic intermediates (like DHAP, the main 
product of Aldolase activity) relative to untreated cells and found evidence that the small 
molecule inhibitor was indeed interfering with cellular glycolytic function.  
Much like the effects that were observed in siRNA mediated functional genomics studies 
putative small molecule inhibitors identified in the high throughput screen were also tested for 
their ability to inhibit cell viability and global HIF activity.  The combination of the XTT viability 
assay and in-house HRE luciferase activity was again used to identify inhibitors of these key 
cellular processes and, as suspected based on the profound level of glycolysis inhibition 
observed in a range of assays, TDZD-8 was identified as a key inhibitor; these results confirmed 
the findings discussed previously regarding the interplay between Aldolase and normal HIF 
function and, through validation of the findings in a panel of cell lines, this small molecule was 
selected as a useful tool compound for future studies. 
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Finally, the validation of the overall findings in each of the in vitro experiments mentioned 
above was carried forward into the same murine model used for shALDOA studies mentioned 
earlier. Intraperitoneal administration of TDZD-8 into these mice had the clear effect of 
recapitulating the anti-tumor activity of ALDOA knockdown by induced shRNA with the added 
evidence of 3PG, DHAP and lactate production inhibition following GC/MS analysis.  
Taken together, these findings suggest that the careful design of high throughput screening 
methodologies through the use of either virtual or in vitro platforms followed by selection of 
promising inhibitors identified using these assays has yielded a promising small molecule 
inhibitor of cancer cell metabolism, stress survival mechanisms, and ultimately tumor 
development and progression. 
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Chapter 4: Summary and Future Directions 
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Solid tumors present researchers with a very unique set of hurdles during the drug 
development process which must be encountered and navigated when considering the specific 
needs in the design of a targeted therapy. Normal glycolytic function is a critical means for 
tumors to generate much needed energy in the form of ATP for the development of new 
biomass as the rapidly dividing cells found within the tumor microenvironment expand [5, 120].  
Because of this rapid expansion of the cells which form them, solid tumors typically outgrow a 
normal vasculature and, therefore, possess poorly organized blood vessels that are often 
described as having erratic and chaotic branching structures [121]. This results in the possible 
separation from functional blood vessels and, subsequently, a hypoxic environment which is 
inherently stressful to normal cells while heavily favoring tumor growth [21-23].  Unlike normal 
cells, a cancer cell’s ability to survive the stress associated with a hypoxic environment is 
ultimately attributed to the expression of the hypoxia inducible transcription factors HIF-1 and 2 
[24, 25] and the cascade of enhanced expression of a range of survival genes which are 
associated with their activity.  Because of their critical functions, both have been extensively 
studied as possible therapeutic targets as means to inhibit tumor growth and cancer cell survival 
[7, 56, 60, 92, 122-125].  Although many attempts have been made to identify HIF specific inhibitors 
through a variety of mechanisms (inhibition of HIF-1 protein synthesis [126] and stabilization [127], 
the transactivation of HIF target genes [128] and even its translocation into the nucleus [129]), drug 
development attempts in this realm have ultimately fallen short. Through the execution of this 
work we are now able to report that because of the previously unknown feed forward 
relationship between glycolysis and HIF activity as a transcription factor, we have uncovered a 
novel target for the inhibition of tumor growth.  
 
Future Directions: Glycolytic Regulation of HIF Activity 
While the finding that there is a clear relationship between ALDOA inhibition and the 
reduction in cellular glycolysis and HIF activity is an interesting one, there are additional 
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experiments that could be conducted in order to further solidify the proposed mechanism of this 
regulation and further understand the molecular basis for this regulation.    
First, in Chapter 1 I outline the fact that AMPK activation following ALDOA knockdown leads 
to the phosphorylation of the p300/CREB binding protein [91].   The subsequent deactivation of its 
transcriptional activity can be attributed to the loss of HIF function without the loss of HIF protein 
expression, a result which we saw in a number of cell lines.  As a possible confirmatory study, 
site directed mutagenesis could be employed to investigate the relationship between p300 
phosphorylation and the ALDOA/HIF feed forward loop. Since we argue here that 
phosphorylation at Ser89 is a critical step in the dissociation of HIF and its critical co-activator, 
mutation of this key residue and overexpression in various cell lines would confirm this finding 
following knockdown of glycolytic enzymes as previously described.  Following ALDOA 
inhibition using this model, Ser89 mutation should result in a rescue of HIF activity in the cell 
and could be measured using a number of the assays described here including HRE-luciferase 
activity and loss of HIF binding in the EMSA assay. 
Second, although we see very little effect of glycolytic enzyme knockdown in cancer cells 
following treatment with normoxic conditions, it would be interesting to investigate the effects 
with both siRNA mediated and putative small molecule inhibitor mediated inhibition of ALDOA 
activity in normal cells.  That said, through the use of available cell lines such as mouse 
embryonic fibroblasts (3T3) or immortalized human fibroblasts, for instance, the effect of 
ALDOA inhibition could be further investigated as a means to selectively disrupt cancer cell 
proliferation while also generating only minimal toxicity in otherwise normal cells and minimal 
side effects compared to traditional therapies in patients. We assume that because of the 
profound differences between cancer and normal cell metabolic pathways of choice that the use 
of normoxic cancer cells in these assays would be proof enough that this kind of novel therapy 
would avoid such toxicity to healthy tissue but the presence of additional genetic confounders 
between the cell populations may warrant additional consideration.  
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Future Directions: TDZD-8 and Analogs’ Mechanism of Action 
In chapter 3, the effects of siRNA mediated ALDOA deletion were recapitulated with a small 
molecule inhibitor identified from a high throughput in vitro small molecule screen with clear 
effects on the inhibition of cellular glycolysis and HIF function as well as antitumor activity in 
mice.  
Despite this fact, the experiments with TDZD-8 do not necessarily point to a clear inhibition 
of ALDOA activity in vivo.  As noted, TDZD-8 was initially marketed as a GSK-3β inhibitor [116] so 
a clear demonstration of ALDOA inhibition in tumors may be critical.  In order to accomplish this, 
it would be interesting to again employ site directed mutagenesis studies at the two key cysteine 
residues mentioned previously (Cys239 and Cys289).  Generation of Cys289Ala mutants and 
the more conservative mutant, Cys289Ser, for comparison will allow for multifaceted follow-up 
work; while the substitution of cysteine by alanine would offer a non-polar alternative thus 
eliminating the possible interaction with TDZD-8, the serine substitution and possible 
participation of this residue in hydrogen bonding would be preserved.  Establishing cell lines 
which express these mutated proteins will provide the tools to carry out several forms of 
confirmatory studies.  First, the in vitro treatment of several cell lines harboring these mutant 
ALDOA proteins with TDZD-8 will provide an early assessment of the drug’s activity as it 
specifically relates to this suspected critical residue.  Additionally, the broader applicability of the 
inhibitor in tumors could be established by using several cell lines both with and without the 
ALDOA mutations by painting a more complete picture using orthotopic models with other 
cancer cell lines.  
Carrying this exciting new inhibitor forward, SAR studies with analogs could provide 
additional insight into its mechanism of action and possible ways to improve the efficacy.  This 
will also require these agents to acceptable pharmacokinetic and pharmacodynamic properties 
thus requiring additional modifications to this tool compound’s structure. Should these initial 
challenges be overcome, however, the inhibition of Aldolase activity could emerge as an 
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exciting novel therapeutic option for patients without the typical side effects associated with 
traditional chemotherapeutic agents. 
 
Summary 
The overarching goal for modern translational research efforts is the design of new agents 
and therapeutic strategies for the inhibition of cancer specific targets in order to spare healthy 
tissue and avoid toxicities associated with a lower quality of life for patients undergoing 
treatment.  Despite years of ongoing research surrounding gene and protein expression 
similarities and differences between cancers and normal tissue, the wide range of targets and 
the heterogeneity found from one individual to the next has confounded even the best attempts 
at new inhibitors and therapies.  As I have discussed here, the use of high throughput screening 
methodologies in carefully designed assays has led to the identification of a novel interplay 
between cancer cell metabolism and the transcriptional activity of the hypoxia inducible factor 
and, as a result, a new therapeutic target has been identified.  With a new small molecule 
inhibitor currently in preclinical investigation, the value of the combination of basic research, 
computational biology, chemistry and pharmaceutical design found within an experimental 
therapeutics program is clear.  The collective knowledge from each of these realms contributed 
to the development of a novel tool compound with great potential for an eventual impactful 
clinical therapy. 
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